

AntiCancer Inc.

MetaMouse

General

1. Dutton, G. AntiCancer Inc. scientists identify a key governing step in the metastasis of cancer. *Genetic Engineering News* 16, 1, January 15, 1996.
2. Holzman, D. Of mice and metastasis: A new for-profit model emerges. *Journal of the National Cancer Institute* 88, 396-397, 1996.
3. Riordan, T. A technique is said to ease attachment of tumors to mice, making them little cancer patients. *New York Times, Patents* □ Column, March 4, 1996.
4. Hoffman, R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. *Investigational New Drugs* 17, 343-359, 1999.
5. Dove, A. Illuminating cancer models. *Nature Biotechnology* 18, 261, 2000.
6. McCann, J. Jellyfish protein gives new glow to tumor imaging. *Journal of the National Cancer Institute* 93, 976-977, 2001.
7. Garber, K. Realistic rodents? Debate grows over new mouse models of cancer. *Journal of the National Cancer Institute* 98, 1176-1178, 2006.
8. Garber, K. From human to mouse and back: tumorgraft □ models surge in popularity. *Journal of the National Cancer Institute* 101, 6-8, 2009.
9. Hiroshima, Y., Maawy, A., Zhang, Y., Zhang, N., Murakami, T., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., Hoffman, R.M. Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. *Oncotarget* 7, 71696-71702, 2016.
10. Hoffman, R.M., ed. Patient-Derived Mouse Models of Cancer. *Molecular and Translational Medicine*. Coleman, W.B., Tsongalis, G.J., Series eds. Springer Intl. Publishing AG, 2017. ISSN:2197-7852.
11. Suetsugu, A., Shimizu, M., Saji, S., Moriwaki, H., Hoffman, R.M. Visualizing the tumor microenvironment (TME) by color-coded imaging in orthotopic mouse models of cancer. *Anticancer Research* **38**, 1847-1857, 2018.
12. Lwin TM, Hoffman RM, Bouvet M. Advantages of patient-derived orthotopic mouse models and genetic reporters for developing fluorescence-guided surgery. *J. Surg. Oncol.* **118**, 253-264, 2018.

Brain cancer and metastasis

1. Yang, M., Jiang, P., Sun, F.X., Hasegawa, S., Baranov, E., Chishima, T., Shimada, H., Moossa, A.R., and Hoffman, R.M. A fluorescent orthotopic bone metastasis model of human prostate cancer. *Cancer Research* 59, 781-786, 1999.
2. Yang, M., Jiang, P., An, Z., Baranov, E., Li, L., Hasegawa, S., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. Genetically fluorescent melanoma bone and organ

AntiCancer Inc.

MetaMouse

- metastasis models. *Clinical Cancer Research* 5, 3549-3559, 1999.
3. Hoffman, R.M. Green fluorescent protein imaging of tumor cells in mice. *Lab Animal* 31, 34-41, 2002.
 4. Hoffman, R.M., and Yang, M. Whole-body imaging with fluorescent proteins. *Nature Protocols* 1, 1429-1438, 2006.
 5. Hayashi, K., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Bouvet, M., Wessels, J., and Hoffman, R.M. A color-coded orthotopic nude-mouse treatment model of brain-metastatic paralyzing spinal cord cancer that induces angiogenesis and neurogenesis. *Cell Proliferation* 42, 75-82, 2009.
 6. Hoffman, R.M. Comment re: Preclinical model of spontaneous melanoma metastasis. *Cancer Research* 69, 719, 2009.
 7. Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C.R., Zhu, Z., Hoffman, R.M., and Kerbel, R.S. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. *Cancer Research* 69, 7243-7251, 2009.
 8. Kimura, H., Zhang, L., Zhao, M., Hayashi, K., Tsuchiya, H., Tomita, K., Bouvet, M., Wessels, J., and Hoffman, R.M. Targeted therapy of spinal cord glioma with a genetically-modified *Salmonella typhimurium*. *Cell Proliferation* 43, 41-48, 2010.
 9. Zhang, Q., Fan, H., Shen, J., Hoffman, R.M., and Xing, H.R. Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. *PLoS One* 5, e9712, 2010. DOI: 10.1371/journal.pone.0009712.
 10. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., Verma, I.M. Transdifferentiation of glioblastoma cells into vascular endothelial cells. *Proc. Natl. Acad. Sci. USA* 108, 4274-4280, 2011. Commentary: Hormigo, A., Ding, B-S., and Rafii, S. A target for antiangiogenic therapy: Vascular endothelium derived from glioblastoma. *Proc. Natl. Acad. Sci. USA* 108, 4271-4272, 2011.
 11. Momiyama, M., Suetsugu, A., Chishima, T., Bouvet, M., Endo, I., and Hoffman, R.M. Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. *Anticancer Res.* 33, 103-106, 2013.
 12. Momiyama, M., Suetsugu, A., Kimura, H., Chishima, T., Bouvet, M., Endo, I., and Hoffman, R.M. Dynamic subcellular imaging of cancer cell mitosis in the brain of live mice. *Anticancer Res.* 33, 1367-1371, 2013.
 13. Momiyama, M., Zhao, M., Kimura, H., Tran, B., Chishima, T., Bouvet, M., Endo, I., and Hoffman R.M. Inhibition and eradication of human glioma with tumor-targeting *Salmonella typhimurium* in an orthotopic nude-mouse model. *Cell Cycle* 11, 628-632, 2012.
 14. Momiyama, M., Hiroshima, Y., Suetsugu, A., Tome, Y., Mii, S., Yano, S., Bouvet, M., Chishima, T., Endo, I., and Hoffman, R.M. Enhanced resection of orthotopic red-fluorescent-protein-

AntiCancer Inc.

MetaMouse

expressing human glioma by fluorescence-guided surgery in nude mice. *Anticancer Res.* 33, 107-112, 2013.

15. Rashidi, B., Moossa, A.R., and Hoffman, R.M. Specific route mapping visualized with GFP of single-file streaming contralateral and systemic metastasis of Lewis lung carcinoma cells beginning within hours of orthotopic implantation. *J. Cell. Biochem* 114, 1738-1743, 2013.

Lung

1. Wang, X., Fu, X., and Hoffman, R.M. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. *Int. J. Cancer* 51, 992-995, 1992. [PDF]
2. Kuo, T-H., Kubota, T., Watanabe, M., Furukawa, T., Kase, S., Tanino, H., Nishibori, K., Saikawa, Y., Teramoto, T., Ishibiki, K., Kitajima, M., and Hoffman, R.M. Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice. *Anticancer Res.* 12, 1407-1410, 1992.[PDF]
3. Wang, X., Fu, X., and Hoffman, R.M. A patient-like metastasizing model of human lung adenocarcinoma constructed via thoracotomy in nude mice. *Anticancer Res.* 12, 1399-1402, 1992. [PDF]
4. Wang, X., Fu, X., Kubota, T., and Hoffman, R.M. A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice. *Anticancer Res.* 12, 1403-1406, 1992. [PDF]
5. Kuo, T-H., Kubota, T., Watanabe, M., Furukawa, T., Kase, S., Tanino, H., Saikawa, Y., Ishibiki, K., Kitajima, M., and Hoffman, R.M. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. *Anticancer Res.* 13, 627-630, 1993. [PDF]
6. Astoul, P., Wang, X., and Hoffman, R.M. "Patient-like" nude- and SCID-mouse models of human lung and pleural cancer (Review). *Int. J. Oncology* 3, 713-718, 1993. [PDF]
7. Astoul, P., Colt, H.G., Wang, X., and Hoffman, R.M. A patient-like nude mouse model of parietal pleural human lung adenocarcinoma. *Anticancer Res.* 14, 85-92, 1994.
8. Astoul, P., Colt, H.G., Wang, X., Boutin, C. and Hoffman, R.M. A patient-like nude mouse metastatic model of advanced human pleural cancer. *Journal of Cellular Biochemistry* 56, 9-15, 1994.[PDF]
9. Astoul, P., Wang, X., Colt, H.G., Boutin, C., and Hoffman, R.M. A patient-like human malignant pleural mesothelioma nude-mouse model. *Oncology Reports* 3, 483-487, 1996.
10. Colt, H.G., Astoul, P., Wang, X., Yi, E.S., Boutin, C., and Hoffman, R.M. Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude

AntiCancer Inc.

MetaMouse

- mouse model. *Anticancer Res.* 16, 633-640, 1996. [PDF]
11. An, Z., Wang, X., Astoul, P., Danays, T., Moossa, A.R., and Hoffman, R.M. Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. *Anticancer Res.* 16, 2545-2551, 1996. [PDF]
 12. Olbina, G., Cieslak, D., Ruzdijic, S., Esler, C., An, Z., Wang, X., Hoffman, R., Seifert, W., and Pietrkowski, Z. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. *Anticancer Res.* 16, 3525-3530, 1996. [PDF]
 13. Yang, M., Hasegawa, S., Jiang, P., Wang, X., Tan, Y., Chishima, T., Shimada, H., Moossa, A.R., and Hoffman, R.M. Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. *Cancer Res.* 58, 4217-4221, 1998. [PDF]
 14. Rashidi, B., Yang, M., Jiang, P., Baranov, E., An, Z., Wang, X., Moossa, A.R., and Hoffman, R.M. A highly metastatic Lewis lung carcinoma orthotopic green fluorescent protein model. *Clinical & Experimental Metastasis* 18, 57-60, 2000. [PDF]
 15. Hoffman, Robert M. Metastatic Mouse Models of Lung Cancer. In: Driscoll, B., ed. *Methods in Molecular Medicine, Vol. 74: Lung Cancer, Vol. 1: Molecular Pathology Methods and Reviews.* Totowa, NJ: Humana Press, 457-464, 2002.. [PDF]
 16. Yamamoto, N., Yang, M., Jiang, P., Tsuchiya, H., Tomita, K., Moossa, A.R., and Hoffman, R.M. Real-time GFP imaging of spontaneous HT-1080 fibrosarcoma lung metastases. *Clin. Exp. Metastasis* 20, 181-185, 2003. [PDF]
 17. Bobek, V., Boubelik, M., Fiserova, A., L'uptovcova, M., Vannucci, L., Kacprzak, G., Kolodziej, J., Majeovski, A.M., and Hoffman R.M. Anticoagulant drugs increase natural killer cell activity in lung cancer. *Lung Cancer* 47, 215-223, 2005.
 18. Hoffman, R.M. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenovirus in an orthotopic model of advanced lung cancer. *Cancer* 109, 1213-1214, 2007. [PDF]
 19. Zhang, C., Lv, F., Zhou, L., Li, X., Wu, X-X., and Hoffman, R.M. Effect of verapamil on the expression of EGFR and NM23 in A549 humanlung cancer cells. *Anticancer Res.* 29, 27-32, 2009.
 20. Kimura, H., Hayashi, K., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Kishimoto, H., Bouvet, M., and Hoffman, R.M. Real-time imaging of single cancer-cell dynamics of lung metastasis. *J. Cell. Biochem.* 109, 58-64, 2010.
 21. Bobek, V., Kolostova, K., Pinterova, D., Boubelik, M., Gurlich, R., and Hoffman, R.M. Tail spontaneous metastatic mouse model: Comparison of metastatic potential of orthotopic and heterotopic models imaged by GFP and RFP protein. *In Vivo* 25, 849-852, 2011.
 22. Bobek, V., Kolostova, K., Pinterova, D., Boubelik, M., and Hoffman, R.M. Development of new spontaneous metastatic heterotopic model of Lewis lung carcinoma imaged by GFP Expression.

AntiCancer Inc.

MetaMouse

Cancer Invest. 29, 692-695, 2011.

23. Zhang, Y., Zhang, N., Su, S., Hoffman, R.M., Zhao, M. Salmonella typhimurium A1-R tumor targeting in immunocompetent mice is enhanced by a Traditional Chinese Medicine herbal mixture. *Anticancer Res.* 33, 1837-1843, 2013.
24. Rashidi, B., Moossa, A.R., and Hoffman, R.M. Specific route mapping visualized with GFP of single-file streaming contralateral and systemic metastasis of Lewis lung carcinoma cells beginning within hours of orthotopic implantation. *J. Cell. Biochem* 114, 1738-1743, 2013.
25. Fang, T., Huang, H., Li, X., Liao, J., Yang, Z., Hoffman, R.M., Cheng, X., Liang, L., Hu, W., Yun, S. Tumor progression in patient-derived xenograft of non-small cell lung cancer is inhibited by sirNA silencing of TUG1 and LCAL6 long non-coding RNAs. *Anticancer Research* **38**, 179-186, 2018.

Breast

1. Fu, X., Le, P., and Hoffman, R.M. A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. *Anticancer Res.* 13, 901-904, 1993. [PDF]
2. Kubota, T., Inoue, S., Furukawa, T., Ishibiki, K., Kitajima, M., Kawamura, E., and Hoffman, R.M. Similarity of serum □ Tumor pharmacokinetics of antitumor agents in man and nude mice. *Anticancer Res.* 13, 1481-1484, 1993.[PDF]
3. Li, X-M., Wang, J-W., An, Z., Yang, M. Baranov, E., Jiang, P., Sun, F-X., Moossa, A.R., and Hoffman, R.M. Optically imageable metastatic model of human breast cancer. *Clinical & Experimental Metastasis*, 19, 347-350, 2002. [PDF]
4. John, C.M., Leffler, H., Kahl-Knutsson, B., Svensson, I., Jarvis, G.A. Truncated Galectin-3 Inhibits Tumor Growth and Metastasis in Orthotopic Nude Mouse Model of Human Breast Cancer. *Clinical Cancer Res.* 9, 3808-3814, 2003 [PDF]
5. Goodison, S., Kawai, K., Hihara, J., Jiang, P., Yang, M., Urquidi, V., Hoffman, R.M., and Tarin, D. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from non-metastatic breast tumors revealed by labeling with green fluorescent protein. *Clinical Cancer Res.* 9, 3808-3814, 2003. [PDF]
6. Tsuji, K., Yamauchi, K., Yang, M., Jiang, P., Bouvet, M., Endo, H., Kanai, Y., Yamashita, K., Moosa, A.R., and Hoffman, R.M. Dual-color imaging of nuclear-cytoplasmic dynamics, viability, and proliferation of cancer cells in portal vein area. *Cancer Res.* 66, 303-306, 2006.[PDF]
7. Drapeau, C., Ma, H., Yang, Z., Tang, L., Hoffman, R.M., and Schaeffer, D.J. The stem cell mobilizer StemEnhance□ does not promote tumor growth in an orthotopic model of human breast cancer. *Anticancer Research* 29, 443-447, 2009.
8. Zhang, Q., Fan, H., Shen, J., Hoffman, R.M., and Xing, H.R. Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. *PLoS*

AntiCancer Inc.

MetaMouse

- One 5, e9712, 2010. DOI: 10.1371/journal.pone.0009712.
9. Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J.Q., Hoffman, R.M., and Karin, M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. *Nature* 470, 548-553, 2011.
 10. Zhang, Q., Bindokas, V.P., Shen, J., Fan, H., Hoffman, R.M., Xing, H.R. Time-course imaging of therapeutic functional tumor vascular normalization by anti-angiogenic agents. *Mol. Cancer Ther.* 10, 1173-1184, 2011.
 11. Hu, M., Zhao, M., An, C., Yang, M., Li, Q., Zhang, Y., Suetsugu, A., Tome, Y., Yano, S., Fu, Y., Hoffman, R.M., and Hu, K. Real-time imaging of apoptosis induction of human breast cancer cells by the traditional Chinese medicinal herb Tubeimu. *Anticancer Res.* 32, 2509-2514, 2012.
 12. Zhang, Y., Tome, Y., Suetsugu, A., Zhang, L., Zhang, N., Hoffman, R.M., and Zhao M. Determination of the optimal route of administration of *Salmonella typhimurium* A1-R to target breast cancer in nude mice. *Anticancer Research* 32, 2501-2508, 2012.
 13. Suetsugu, A., Honma, K., Saji, S., Moriwaki, H., Ochiya, T., and Hoffman, R.M. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude mouse models. *Adv. Drug Deliv. Rev.* 65, 383-390, 2013.
 14. Hoffman, R.M. Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche. *Breast Cancer Res.* 15, 310-313, 2013.
 15. Wu, J., Ma, R., Cao, H., Wang, Z., Jing, C., Sun, Y., Zhang, Y., Yang, Z., Hoffman, R.M., and Tang, J. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model. *Anticancer Research* 33, 419-424, 2013.
 16. Ke, C-C., Liu, R-S., Suetsugu, A., Kimura, H., Ho, J.H., Lee, O.K., and Hoffman, R.M. In vivo fluorescence imaging reveals the promotion of mammary tumorigenesis by mesenchymal stromal cells. *PLoS One* 8, e69658, 2013.

Colon

1. Fu, X., Besterman, J.M., Monosov, A., and Hoffman, R.M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. *Proc. Natl. Acad. Sci. USA* 88, 9345-9349, 1991.[PDF]
2. Fu, X., Herrera, H., Kubota, T., and Hoffman, R.M. Extensive liver metastasis from human colon cancer in nude and SCID mice after orthotopic onplantation of histologically-intact human colon carcinoma tissue. *Anticancer Res.* 12, 1395-1398, 1992.[PDF]
3. Furukawa, T., Kubota, T., Watanabe, M., Kuo, T.H., Kase, S., Saikawa, Y., Tanino, H., Teramoto, T., Ishibiki, K., Kitajima, M., and Hoffman, R.M. Immunochemotherapy prevents human colon cancer metastasis after orthotopic onplantation of histologically-intact tumor tissue in nude mice.

AntiCancer Inc.

MetaMouse

- Anticancer Res. 13, 287-291, 1993. [PDF]
4. Kuo, T-H., Kubota, T., Watanabe, M., Furukawa, T., Teramoto, T., Ishibiki, K., Kitajima, M., and Hoffman, R.M. Early resection of primary orthotopically-growing human colon tumor in nude mouse prevents liver metastasis: further evidence for patient-like hematogenous metastatic route. Anticancer Res. 13, 293-297, 1993. [PDF]
 5. Furukawa, T., Kubota, T., Watanabe, M., Kuo, T-H., Nishibori, H., Kase, S., Saikawa, Y., Tanino, H., Teramoto, T., Ishibiki, K., and Kitajima, M. A metastatic model of human colon cancer constructed using cecal implantation of cancer tissue in nude mice. Jpn. J. Surg. 23, 420-423, 1993. [PDF].
 6. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J., and Hoffman, R.M. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54, 4726-4728, 1994.. [PDF]
 7. Togo, S., Shimada, H., Kubota, T., Moossa, A.R., Hoffman, R.M. 鉄eed□ to 都oil□ is a return trip in metastasis. Anticancer Res. 15, 791-794, 1995.[PDF]
 8. Togo, S., Shimada, H., Kubota, T., Moossa, A.R., Hoffman, R.M. Host organ specifically determines cancer progression. Cancer Res. 55, 681-684, 1995.[PDF]
 9. Kuo, T-H., Kubota, T., Watanbe, M., Furukawa, T., Teramoto, T., Ishibiki, K., Kitajimi, M., Moossa, A.R., Penman, S., Hoffman, R.M. Liver colonization competence governs colon cancer metastasis. Proc. Natl. Acad. Sci. USA 92, 12085-12089, 1995.[PDF]
 10. Togo, S., Wang, X., Shimada, H., Moossa, A.R., and Hoffman, R.M. Cancer seed and soil can be highly selective: Human-patient colon tumor lung metastasis grows in nude mouse lung but not colon or subcutis. Anticancer Res. 15, 795-798, 1995.[PDF]
 11. Leff, D.N. MetaMouse models colon cancer metastasis with clinical potential. BioWorld Today 7, 1, January 8, 1996. [PDF]
 12. Murray, G., Duncan, M., O 誰 eil, P., Melvin, W., Fothergill, J. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Medicine 2, 461-462, 1996. [PDF]
 13. An, Z., Wang, X., Willmott, N., Chander, S.K., Tickle, S., Docherty, A.J., Mountain, A., Millican, A.T., Morphy, R., Porter, J.R., Epemolu, R.O., Kubota, T., Moossa, A.R., and Hoffman, R.M. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clinical & Experimental Metastasis 15, 184-195, 1997. [PDF]
 14. Sun, F-X., Sasson, A.R., Jiang, P., An, Z., Gamagami, R., Li, L., Moossa, A.R., and Hoffman, R.M. An ultra-metastatic model of human colon cancer in nude mice. Clinical & Experimental Metastasis 17, 41-48, 1999. [PDF]
 15. Sasson, A.R., Gamagami, R., An, Z., Wang, X., Moossa, A.R., and Hoffman, R.M. Cimetidine: An inhibitor or promoter of tumor growth? International Journal of Cancer 81, 835-838, 1999.

AntiCancer Inc.

MetaMouse

[PDF]

16. Rho, Y-S., Lee, K-T., Jung, J-C., Yoon, C., An, Z., Hoffman, R.M., and Chang, S-G. Efficacy of new platinum analog DPPE in an orthotopic nude mouse model of human colon cancer. *Anticancer Res.* 19, 157-162, 1999. [PDF]
17. Rashidi, B., An, Z., Sun, F-X., Sasson, A., Gamagami, R., Moossa, A.R., Hoffman, R.M. Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice. *Clinical & Experimental Metastasis* 17, 497-500, 1999. [PDF]
18. Rashidi, B., Sun, F-X., Jiang, P., An, Z., Gamagami, R., Moossa, A.R., and Hoffman, R.M. A nude mouse model of massive liver and lymph node metastasis of human colon cancer. *Anticancer Res.* 20, 715-722, 2000. [PDF]
19. Rashidi, B., An, Z., Sun, F-X., Moossa, A.R., and Hoffman, R.M. Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice. *Clinical Cancer Res.* 6, 2464-2468, 2000.[PDF]
20. Rashidi, B., Gamagami, R., Sasson, A., Sun, F-X., Geller, J., Moossa, A.R., and Hoffman, R.M. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. *Clinical Cancer Res.* 6, 2556-2561, 2000. [PDF]
21. Tsuji, K., Yamauchi, K., Yang, M., Jiang, P., Bouvet, M., Endo, H., Kanai, Y., Yamashita, K., Moosa, A.R., and Hoffman, R.M. Dual-color imaging of nuclear-cytoplasmic dynamics, viability, and proliferation of cancer cells in portal vein area. *Cancer Res.* 66, 303-306, 2006.[PDF]
22. Lukashev, M., LePage, D., Wilson, C., Bailly, V., Garber, E., Lukashin, A., Ngam-ek, A., Zeng, W., Allaire, N., Perrin, S., Xu, X., Szeliga, K., Wortham, K., Kelly, R., Bottiglio, C., Ding, J., Griffith, L., Heaney, G., Silverio, E., Yang, W., Jarpe, M., Fawell, S., Reff, M., Carmillo, A., Miatkowski, K., Amatucci, J., Crowell, T., Prentice, H., Meier, W., Violette, S.M., Mackay, F., Yang, D., Hoffman, R., and Browning, J.L. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. *Cancer Research* 66, 9617-9624, 2006.[PDF]
23. Ji, Y., Hayashi, K., Amoh, Y., Tsuji, K., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Bouvet, M., and Hoffman, R.M. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. *Anticancer Res.* 27, 713-718, 2007.[PDF]
24. Hayashi, K., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Amoh, Y., Hoffman, R.M., and Bouvet, M. Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma. *J. Surg. Res.* 140, 165-170, 2007. [PDF]
25. Guo, X-N., Rajput, A., Rose, R., Hauser, J., Beko, A., Kuropatwinski, K., LeVe, C., Hoffman, R.M., Brattain, M.G., and Wang, J. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. *Cancer Res.* 67, 5851-5858, 2007. [PDF]
26. Rajput, A., Dominguez San Martin, I., Rose, R., Beko, A., Levea, C., Sharratt, E., Mazurchuk, R.,

AntiCancer Inc.

MetaMouse

- Hoffman, R.M., Brattain, M.G., and Wang, J. Characterization of HCT116 human colon cancer cells in an orthotopic model. *J. Surg. Res.* 147, 276-281, 2008.
27. Sakuma, S., Yano, T., Masaoka, Y., Kataoka, M., Hiwatari, K., Tachikawa, H., Shoji, Y., Kimura, R., Ma, H., Yang, Z., Tang, L., Hoffman, R.M., Yamashita, S. In vitro/in vivo biorecognition of lectin-immobilized fluorescent nanospheres for human colorectal cancer cells. *Journal of Controlled Release* 134, 2-10, 2009.
28. Ma, H., Das, T., Pereira, S., Yang, Z., Zhao, M., Mukerji, P., and Hoffman, R.M. Efficacy of dietary antioxidants combined with a chemotherapeutic agent on human colon cancer progression in a fluorescent orthotopic mouse model. *Anticancer Research* 29, 2421-2426, 2009.
29. Sakuma, S., Yano, T., Masaoka, Y., Kataoka, M., Hiwatari, K.I., Tachikawa, H., Shoji, Y., Kimura, R., Ma, H., Yang, Z., Tang, L., Hoffman, R.M., and Yamashita, S. Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. *Eur. J. Pharma. Biopharma.* 74, 451-460, 2010. DOI: 10.1016/j.ejpb.2010.01.001.
30. Ishihara, Y., Matsunaga, K., Iijima, H., Hasegawa, G., Suzuki, T., Sato, A., Kobayashi, T., Yang, M., and Hoffman, R.M. The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer. *Anticancer Res.* 30, 403-408, 2010.
31. Suetsugu, A., Osawa, Y., Nagaki, M., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Imaging the recruitment of cancer-associated fibroblasts by liver-metastatic colon cancer. *J. Cell. Biochem.* 112, 949-953, 2011.
32. Kishimoto, H., Aki, R., Urata, Y., Bouvet, M., Momiyama, M., Tanaka, N., Fujiwara, T., Hoffman, R.M. Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. *Cell Cycle* 10, 2737-2741, 2011.
33. Sakuma, S., Yamashita, S., Hiwatari, K., Hoffman, R.M., and Pham, W. Lectin-immobilized fluorescent nanospheres for targeting to colorectal cancer from a physicochemical perspective. *Curr. Drug Discov. Technol.* 8, 367-378, 2011.
34. Momiyama, M., Kumamoto, T., Suetsugu, A., Kishimoto, H., Chishima, T., Tanaka, K., Akiyama, H., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Major liver resection stimulates stromal recruitment and metastasis compared with repeated minor resection. *J. Surg. Res.* 178, 280-287, 2012.
35. Metildi, C.A., Kaushal, S., Snyder, C.S., Hoffman, R.M., and Bouvet, M. Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model. *J. Surg. Res.* 179, 87-93, 2013.
36. Metildi, C.A., Kaushal, S., Luiken, G.A., Talamini, M.A., Hoffman, R.M., and Bouvet, M. Fluorescently-labeled chimeric anti-CEA antibody improves detection and resection of human

AntiCancer Inc.

MetaMouse

- colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J Surg. Oncol.* **109**, 451-458, 2014.
37. Hiroshima, Y., Maawy, A., Metildi, C.A., Zhang, Y., Uehara, F., Miwa, S., Yano, S., Sato, S., Murakami, T., Momiyama, M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. *J. Laparoendosc. Adv. Surg. Tech. A* **24**, 241-247, 2014.
 38. Park JH, Zhao M, Oshiro H, Miyake K, Higuchi T, Reynoso J, Razmjooei S, Bouvet M, Clary B, Zhang Z, Sugisawa N, Yamamoto J, Singh SR, Hoffman RM. Peritoneal Metastases in a Patient-derived Orthotopic Xenograft (PDOX) Model of Colon Cancer Imaged Non-invasively via Red Fluorescent Protein Labeled Stromal Cells. *Anticancer Res.* 39(7): 3463-3467. 2019
 39. Park JH, Zhao M, Han Q et al. Efficacy of oral recombinant methioninase combined with oxaliplatin and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. *Biochem Biophys Res Commun* 2019; 518: 306- 310.
 40. Zhu G, Zhao M, Han Q, Tan Y, Sun YU, Bouvet M, Singh SR, Ye J, Hoffman RM. Combination of Trabectedin With Oxaliplatin and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. *Anticancer Res.* 2019 Nov;39(11):5999-6005. doi: 10.21873/anticancerres.13805.
 41. Park JH, Han Q, Zhao M, Tan Y, Higuchi T, Yoon SN, Sugisawa N, Yamamoto J, Bouvet M, Clary B, Singh SR, Hoffman RM. Oral recombinant methioninase combined with oxaliplatin and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. *Tissue Cell.* 2019 Dec;61:109-114. doi: 10.1016/j.tice.2019.09.006.
 42. Zhu G, Zhao M, Han Q, Tan Y, Sun YU, Bouvet M, Clary B, Singh SR, Ye J, Hoffman RM. Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.. *Anticancer Res.* 2019 Dec;39(12):6463-6470. doi: 10.21873/anticancerres.13860.
 43. Hollandsworth HM, Amirfakhri S, Filemoni F, Schmitt V, Wennemuth G, Schmidt A, Hoffman RM, Singer BB, Bouvet M. Anti-carcinoembryonic antigen-related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient-derived orthotopic xenograft mouse models. *Oncotarget.* 2020 Jan 28;11(4):429-439. doi: 10.18632/oncotarget.27446.
 44. Zhu G, Zhao M, Han Q, Tan Y, Sun Y, Bouvet M, Clary B, Singh SR, Ye J, Hoffman RM. Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. *Transl Oncol.* 2020 Mar 3;13(3):100739. doi: 10.1016/j.tranon.2019.12.011.

Rectal

AntiCancer Inc.

MetaMouse

1. Kishimoto, H., Momiyama, M., Aki, R., Kimura, H., Suetsugu, A., Bouvet, M., Fujiwara, T., and Hoffman, R.M. Development of a clinically-precise mouse model of rectal cancer. *PLoS One* 11, e79453, 2013.

Stomach

1. Furukawa, T., Fu, X., Kubota, T., Watanabe, M., Kitajima, M., and Hoffman, R.M. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. *Cancer Res.* 53, 1204-1208, 1993. [PDF]
2. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., and Hoffman, R.M. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: Correlation of metastatic sites in mouse and individual patient donors. *Int. J. Cancer* 53, 608-612, 1993. [PDF]
3. Furukawa, T., Kubota, T., Watanabe, M., Kuo, T-H., Kitajima, M., and Hoffman, R.M. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. *Int. J. Cancer* 54, 397-401, 1993. [PDF]
4. Inada, T., Ichikawa, A., Kubota, T., Ogata, Y., Moossa, A.R., and Hoffman, R.M. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. *Anticancer Res.* 17, 1965-1971, 1997. [PDF]
5. Hasegawa, S., Yang, M., Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. *Cancer Gene Therapy* 7, 1336-1340, 2000. [PDF]
6. Kamiyama, M., Ichikawa, Y., Ishikawa, T., Chishima, T., Hasegawa, S., Hamaguchi, Y., Nagashima, Y., Miyagi, Y., Mitsuhashi, M., Hyndman, D., Hoffman, R.M., Ohki, S., and Shimada, H. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. *Cancer Gene Therapy* 9, 197-201, 2002. [PDF]

Esophageal

1. Gros, S.J., Dohrmann, T., Peldschus, K., Schurr, P.G., Kaifi, J.T., Kalinina, T., Reichelt, U., Mann, O., Strate, T.G., Adam, G., Hoffman, R.M., and Izbicki, J.R. Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. *International Journal of Cancer* 126, 2671-2681, 2010.
2. Gros, S., Kurschat, N., Dohrmann, T., Reichelt, U., Dancau, A-M., Peldschus, K., Adam, G., Hoffman, R.M., Izbicki, J.R., and Kaifi, J.T. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. *Molecular Cancer Therapeutics* 9, 2037-2045, 2010.

AntiCancer Inc.

MetaMouse

3. Gros, S.J., Dohrmann, T., Kaifi, J.T., Bouvet, M., Hoffman, R.M., Izbicki, J.R. Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer. *Anticancer Research* 30, 3933-3938, 2010.
4. Gros, S.J., Kurschat, N., Drenckhan, A., Dohrmann, T., Forberich, E., Effenberger, K., Reichelt, U., Hoffman, R.M., Pantel, K., Kaifi, J.T., and Izbicki, J.R. Involvement of CXCR-4 chemokine receptor in metastatic HER2-positive esophageal cancer. *PLoS One* 7(10), e47287, 2012.

Pancreas

1. Fu, X., Guadagni, F., and Hoffman, R.M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. *Proc. Natl. Acad. Sci. USA* 89, 5645-5649, 1992. [PDF]
2. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., and Hoffman, R.M. A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. *Cancer Res.* 53, 3070-3072, 1993.
3. An, Z., Wang, X., Kubota, T., Moossa, A.R., Hoffman, R.M. A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. *Anticancer Res.* 16, 627-631, 1996.
4. Tomikawa, M., Kubota, T., Matsuzaki, S.W., Takahasi, S., Kitajima, M., Moossa, A.R., and Hoffman, R.M. Mitomycin C and cisplatin increase survival in a human pancreatic cancer metastatic model. *Anticancer Res.* 17, 3623-3626, 1997.
5. Bouvet, M., Yang, M., Nardin, S., Wang, X., Jiang, P., Baranov, E., Moossa, A.R., Hoffman, R.M. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. *Clinical & Experimental Metastasis* 18, 213-218, 2000.
6. Lee, N.C., Bouvet, M., Nardin, S., Jiang, P., Baranov, E., Rashidi, B., Yang, M., Wang, X., Moossa, A.R., and Hoffman, R.M. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. *Clinical & Experimental Metastasis* 18, 379-384, 2001. [PDF]
7. Bouvet, M., Wang, J-W., Nardin, S.R., Nassirpour, R., Yang, M., Baranov, E., Jiang, P., Moossa, A.R., and Hoffman, R.M. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. *Cancer Research* 62, 1534-1540, 2002. [PDF]
8. Bouvet, M., Nardin, S.R., Burton, D.W., Lee, N.C., Yang, M., Wang, X., Baranov, E., Behling, C., Moossa, A.R., Hoffman, R.M., and Deftos L.J. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma. *Pancreas* 24, 284-290, 2002.
9. Sun, F-X., Tohgo, A., Bouvet, M., Yagi, S., Nassirpour, R., Moossa, A.R., and Hoffman, R.M. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. *Cancer Research* 63, 80-85, 2003. [PDF]
10. Katz, M., Takimoto, S., Spivac, D., Moossa, A.R., Hoffman, R.M., Bouvet, M. A novel red

AntiCancer Inc.

MetaMouse

- fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. *J.Surg. Res.* 113, 151-160, 2003.[PDF]
11. Katz, M.H., Bouvet, M., Takimoto, S., Spivac, D., Moossa, A.R., Hoffman, R.M. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. *Cancer Res.* 63, 5521-5525, 2003.[PDF]
 12. Tsuji, K., Yamauchi, K., Jiang, P., Yang, M., and Hoffman, R.M. Common bile duct injection as a novel method for establishing RFP-expressing human pancreatic cancer in nude mice. *Journal of the Pancreas* 7, 193-199, 2006.
 13. Katz, M., Spivac, D., Takimoto, S., Bouvet, M., Moosa, A.R., R.M. Hoffman. An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. *Clin. Exp. Metastasis* 21, 7-12, 2004.[PDF]
 14. Katz, M.H., Bouvet, M., Takimoto, S., Spivack, D., Moosa, A.R., and Hoffman, R.M. Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer. *Cancer Research* 64, 1828-1833, 2004. [PDF]
 15. Bouvet, M., Spornyak, J., Katz, M.H., Mazurchuk, R.V., Takimoto, S., Bernacki, R., Rustum, Y.M., Moossa, A.R., and Hoffman, R.M. High correlation of whole- body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. *Cancer Research* 65, 9829-9833, 2005. [PDF]
 16. Amoh, Y., Li, L., Tsuji, K., Moosa, A.R., Katsuoka, K., Hoffman, R.M., Bouvet, M. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antioangiogenesis efficacy of gemcitabine. *J. Surgical Research* 132, 164-169, 2006.
 17. Amoh, Y., Nagakura, C., Maitra, A., Moossa, A.R., Katsuoka, K., Hoffman, R.M., and Bouvet, M. Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. *Anticancer Research* 26, 3237-3242, 2006.[PDF]
 18. Bouvet, M., Hoffman R.M. Preclinical fluorescent mouse models of pancreatic cancer. *Proc. of SPIE* 6449, 64490X-1 - 64490X-11, 2007.[PDF]
 19. Ammons, W.S., Wang, J.W., Yang, Z., Tidmarsh, G.F., and Hoffman, R.M. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. *Neoplasia* 9, 625-633, 2007.[PDF]
 20. Kaushal, S., McElroy, M.K., Luiken, G.A., Talamini, M.A., Moossa, A.R., Hoffman, R.M., and Bouvet, M. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. *J. Gastrointest. Surg.* 12, 1938-1950, 2008.
 21. Tran Cao, H.S., Kimura, H., Kaushal, S., Snyder, C.S., Reynoso, J., Hoffman, R.M., and Bouvet, M. The cyan fluorescent protein (CFP) transgenic mouse as a model for imaging pancreatic exocrine cells. *Journal of the Pancreas* 10, 152-156, 2009.
 22. Tran Cao, H.S., Reynoso, J., Yang M., Kimura, H., Kaushal, S., Snyder, C.S., Hoffman, R.M., and

AntiCancer Inc.

MetaMouse

- Bouvet M. Development of the transgenic cyan fluorescent protein (CFP)-expressing nude mouse for technicolor cancer imaging. *J. Cell. Biochem* 107, 328-334, 2009.
23. Snyder, C.S., Kaushal, S., Kono, Y., Tran Cao, H.S., Hoffman, R.M., and Bouvet, M. Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer. *BMC Cancer* 9, 106, 2009. DOI: 10.1117/1.3103783.
 24. Matsuo, Y., Raimondo, M., Woodward, T.A., Wallace, M.B., Gill, K.R., Tong, Z., Burdick, M.D., Yang, Z., Strieter, R.M., Hoffman, R.M., Guha, S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. *Int. J. Cancer* 125, 1027-1037, 2009.
 25. Nagakura, C., Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Bouvet, M., and Hoffman, R.M. Efficacy of a genetically-modified *Salmonella typhimurium* in an orthotopic human pancreatic cancer in nude mice. *Anticancer Res.* 29, 1873-1878, 2009.
 26. Zhou, J., Yu, Z., Zhao, S., Hu, L., Zheng, J., Yang, D., Bouvet, M., Hoffman, R.M. Lentivirus-based DsRed-2-transfected pancreatic cancer cells for deep in vivo imaging of metastatic disease. *J. Surg. Res.* 157, 63-70, 2009.
 27. Bouvet, M., and Hoffman, R.M. Clinically-relevant orthotopic metastatic models of pancreatic cancer imageable with fluorescent genetic reporters. *Minerva Chirurgica* 64, 521-539, 2009.
 28. Logan-Collins, J., Thomas, R.M., Yu, P., Jaquish, D., Mose, E., French, R., Stuart, W., McClaine, R., Aronow, B., Hoffman, R.M., Waltz, S.E., and Lowy, A.M. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. *Cancer Res.* 70, 1130-40, 2010. DOI: 10.1158/0008-5412.CAN-09-0761.
 29. Murphy, E.A., Shields, D.J., Stoletov, K., Dneprovskaja, E., McElroy, M., Greenberg, J.I., Lindquist, J., Acevedo, L.M., Anand, S., Majeti, B.K., Tsigelny, I., Saldanha, A., Walsh, B., Hoffman, R.M., Bouvet, M., Klemke, R.L., Vogt, P.K., Arnold, L., Wrasidlo, W., and Cheresch, D.A. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFR β /B-RAF. *Proc. Natl. Acad. Sci. USA* 107, 4299-4304, 2010. DOI: 10.1073/pnas.0909299107.
 30. Tran Cao, H.S., Bouvet, M., Kaushal, S., Keleman, A., Romney, E., Kim, G., Fruehauf, J., Imagawa, D.K., Hoffman, R.M., and Katz, M. Metronomic gemcitabine in combination with Sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. *Molecular Cancer Therapeutics* 9, 2068-2078, 2010. (Highlights Section. *Molecular Cancer Therapeutics* 9, 1929, 2010).
 31. Tran Cao, H., Kaushal, S., Lee, C., Snyder, C.S., Thompson, K.J., Horgan, S., Talamini, M.A., Hoffman, R.M., and Bouvet, M. Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model. *Surg. Endosc.* 25, 48-54, 2011.
 32. Tran Cao, H.S., Kaushal, S., Menen, R.S., Metildi, C.A., Lee, C., Snyder, C.S., Talamini, M.A.,

AntiCancer Inc.

MetaMouse

- Hoffman, R.M., and Bouvet, M. Submillimeter-resolution fluorescence laparoscopy of pancreatic cancer in a carcinomatosis mouse model visualizes metastases not seen with standard laparoscopy. *J. Laparoendosc. Adv. Surg. Tech. A* 21, 485-489, 2011 (Cover story).
33. Grzesiak, J.J., Tran Cao, H.S., Burton, D.W., Kaushal, S., Vargas, F., Clopton, P., Snyder, C.S., Deftos, L.J., Hoffman, R.M., and Bouvet, M. Knockdown of the $\beta 1$ integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. *International Journal of Cancer* 129, 2905-2915, 2011.
 34. Hassanein, M.K., Suetsugu, A., Saji, S., Moriwaki, H., Bouvet, M., Moossa, A.R., and Hoffman, R.M. Stem-like and non-stem human pancreatic cancer cells distinguished by morphology and metastatic behavior. *Journal of Cellular Biochemistry* 112, 3549-3554, 2011 (Cover story).
 35. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens. *Anticancer Research* 32, 1175-1180, 2012.
 36. Kelber, J.A., Reno, T., Kaushal, S., Metildi, C., Wright, T., Stoletov, K., Weems, J.M., Park, F.D., Mose, E., Wang, Y., Hoffman, R.M., Lowy, A.M., Bouvet, M., and Klemke, R.L. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. *Cancer Research* 72, 2554-2564, 2012.
 37. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Moriwaki, H., Bouvet, M., Saji, S., and Hoffman, R.M. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. *J. Cell. Biochem.* 113, 2290-2295, 2012.
 38. Metildi, C.A., Kaushal, S., Lee, C., Hardamon, C.R., Snyder, C.S., Luiken, G.A., Talamini, M.A., Hoffman, R.M., and Bouvet, M. An LED light source and novel fluorophore combinations improve fluorescence laparoscopic detection of metastatic pancreatic cancer in orthotopic mouse models. *J. Am. Coll. Surg.* 214, 997-1007, 2012.
 39. Bouvet, M., and Hoffman, R.M. In vivo imaging of pancreatic cancer with fluorescent proteins in mouse models (Chap. 4). In *In Vivo Cellular Imaging Using Fluorescent Proteins: Methods and Protocols*. Hoffman, R.M., ed. *Methods in Molecular Biology*, Vol. 872. Walker, John M., series ed. Humana Press (Springer Science+Business Media New York), 2012.
 40. Yu, Z., Zhou, J., and Hoffman, R.M. Lentivirus-based DsRed-2-transfected pancreatic cancer cells for deep in vivo imaging of metastatic disease (Chap. 5). In: *In Vivo Cellular Imaging Using Fluorescent Proteins: Methods and Protocols*. Hoffman, R.M., ed. *Methods in Molecular Biology*, Vol. 872. Walker, John M., series ed. Humana Press (Springer Science+Business Media New York), 2012.

AntiCancer Inc.

MetaMouse

41. Suetsugu, A., Katz, M., Fleming, J., Moriwaki, H., Bouvet, M., Saji, S., and Hoffman, R.M. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. *J. Cell. Biochem.* **113**, 2290-2295, 2012.
42. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens. *Anticancer Research* **32**, 1175-1180, 2012.
43. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. *Anticancer Research* **32**, 3063-3068, 2012.
44. Tran Cao, H.S., Kaushal, S., Metildi, C.A., Menen, R.S., Lee, C., Snyder, C.S., Messer, K., Pu, M., Luiken, G.A., Talamini, M.A., Hoffman, R.M., and Bouvet, M. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. *Hepatology* **59**(118), 1994-1999, 2012. DOI: 10.5754/hge11836.
45. Shi, Y., Tong, M., Wu, Y., Yang, Z., Hoffman, R.M., Zhang, Y., Tian, Y., Qi, M., Lin, Y., Liu, Y., Dai, L., Sun, Y., and Wang, Z. VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model. *Anticancer Research* **33**, 409-417, 2013.
46. Snyder, C.S., Harrington, A.R., Kaushal, S., Mose, E., Lowy, A.M., Hoffman, R.M., and Bouvet, M. A dual-color genetically engineered mouse model for multispectral imaging of the pancreatic microenvironment. *Pancreas* **42**, 952-958, 2013.
47. Zhang, L., Wu, C., Zhang, Y., Liu, F., Zhao, M., Bouvet, M., and Hoffman, R.M. Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer. *J. Cell. Biochem.* **114**, 2131-2137, 2013.
48. Hiroshima, Y., Zhao, M., Zhang, Y., Maawy, A., Hassanein, M.K., Uehara, F., Miwa, S., Yano, S., Momiyama, M., Suetsugu, A., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Comparison of efficacy of *Salmonella typhimurium* A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. *Cell Cycle* **12**, 2774-2780, 2013.
49. Miwa, S., Yano, S., Hiroshima, Y., Tome, Y., Uehara, F., Mii, S., Efimov, E.V., Kimura, H., Hayashi, K., Tsuchiya, H., Hoffman, R.M. Imaging UVC-induced DNA damage response in models of minimal cancer. *J. Cell. Biochem.* **114**, 2493-2499, 2013.
50. Metildi, C.A., Kaushal, S., Hoffman, R.M., and Bouvet, M. In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status. *J. Surg. Res.* **184**, 290-298, 2013.
51. Maawy, A.A., Hiroshima, Y., Kaushal, S., Luiken, G.A., Hoffman, R.M., and Bouvet, M.

AntiCancer Inc.

MetaMouse

- Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orthotopic nude mouse models. *J. Biomed. Optics* **18**, 126016, 2013.
52. Hiroshima, Y., Maawy, A., Sato, S., Murakami, T., Uehara, F., Miwa, S., Yano, S., Momiyama, M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice. *J. Surg. Res.* **187**, 510-517, 2014.
53. Hiroshima, Y., Zhao, M., Maawy, A., Zhang, Y., Katz, M.H., Fleming, J.B., Uehara, F., Miwa, S., Yano, S., Momiyama, M., Suetsugu, A., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Efficacy of *Salmonella typhimurium* A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). *J. Cell. Biochem.* **115**, 1254-1261, 2014.
54. Hiroshima, Y., Maawy, A., Zhang, Y., Murakami, T., Momiyama, M., Mori, R., Matsuyama, R., Katz, M.H., Fleming, J.B., Chishima, T., Tanaka, K., Ichikawa, Y., Endo, I., Hoffman, R.M., and Bouvet, M. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore. *PLoS One* **9**, e114310, 2014.
55. Hiroshima, Y., Zhang, Y., Murakami, T., Maawy, A.A., Miwa, S., Yamamoto, M., Yano, S., Sato, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., Zhao, M., and Hoffman, R.M. Efficacy of tumor-targeting *Salmonella typhimurium* A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. *Oncotarget* **5**, 12346-12357, 2014.
56. Yano, S., Hiroshima, Y., Maawy, A., Kishimoto, H., Suetsugu, A., Miwa, S., Toneri, M., Yamamoto, M., Katz, M.H.G., Fleming, J.B., Urata, Y., Tazawa, H., Kagawa, S., Bouvet, M., Fujiwara, T., and Hoffman, R.M. Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery. *Cancer Gene Therapy* **22**, 344-350, 2015.
57. Jun, E., Jung, J., Jeong, S-Y., Choi, E.K., Kim, M. B., Lee, J. S., Hong, S-M., Seol, H. S., Hwang, C., Hoffman, R.M., Shim, I. K., Chang, S., and Kim, S. C. Surgical and oncological factors affecting the successful engraftment of patient-derived xenografts in pancreatic ductal adenocarcinoma. *Anticancer Res.* **36**, 517-522, 2016.
58. Hoffman, R.M., and Bouvet, M. Imaging the microenvironment of pancreatic cancer patient-derived orthotopic xenografts (PDOX) growing in transgenic nude mice expressing GFP, RFP, or CFP. *Cancer Letters (Special Issue: Tumor Microenvironment. Singh, Shree Ram, ed.)*, **380**, 349-355, 2016.

AntiCancer Inc.

MetaMouse

59. Hoover, M., Adamian, Y., Brown, M., Maawy, A., Chang, A., Lee, J., Gharibi, A., Katz, M.H., Fleming, J., Hoffman, R.M., Bouvet, M., Doebler, R., and Kelber J.A. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. *Oncotarget* **8**, 5885-5894, 2017. **(Cover story)**
60. Kawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Lwin, T., Hwang, H-K., DeLong, J., Clary, B., Bouvet, M., Unno, M., and Hoffman, R.M. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX). *Oncotarget* **8**, 47490-47496, 2017.
61. Jun, E., Hong, S-M., Yoo, H.J., Kim, M.B., Won, J.S., An, S., Shim, I.K., Chang, S., Hoffman, R.M., Kim, S.C. Molecular-genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. *Oncotarget* **9**, 7867-7881, 2018.
62. Kawaguchi, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Miyake, K., Kiyuna, T., Miyake, M., Chmielowski, B., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Singh, A.S., Eckardt, M.A., Unno, M., Eilber, F.C., Hoffman, R.M. Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. *Oncotarget* **9**, 11119-11125, 2018.
63. Kawaguchi, K., Igarashi, K., Miyake, K., Lwin, T.M., Miyake, M., Kiyuna, T., Hwang, H.K., Murakami, T., DeLong, J.C., Singh, R.S., Clary, B., Bouvet, M., Unno, M., Hoffman, R.M. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. *Tissue and Cell* **52**, 124-128, 2018.
64. Kawaguchi, K., Miyake, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Lwin, T.M., Higuchi, T., Kiyuna, T., Miyake, M., Oshiro, H., Bouvet, M., Unno, M., Hoffman, R.M. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. *Cell Cycle* **17**, 868-873, 2018.
65. Kawaguchi K, Miyake K, Han Q, Li S, Tan Y, Igarashi K, Kiyuna T, Miyake M, Higuchi T, Oshiro H, Zhang Z, Razmjooei S, Wangsiricharoen S, Bouvet M, Singh SR, Unno M, Hoffman RM. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. *Cancer Lett*, **432**, 251-259. 2018.
66. Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M, Higuchi T, Oshiro H, Bouvet M, Unno M, Hoffman RM. Tumor targeting *Salmonella typhimurium* A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. *Cell Cycle*. in press, doi: 10.1080/15384101.2018.1480223. 2018.

AntiCancer Inc.

MetaMouse

67. Lwin TM, Miyake K, Murakami T, DeLong JC, Amirfakhri S, Filemoni F, Yoon SN, Yazaki PJ, Shivley JE, Datnow B, Clary BM, Hoffman RM, Bouvet M. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget*. 8;9(99):37333-37342. 2018.

Liver

1. Sun, F.X., Tang, Z.Y., Liu, K.D., Ye, S.L., Xue, Q., Gao, D.M., and Ma, Z.C. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. *Int. J. Cancer* 66, 239-243, 1996. [PDF]
2. Sun, F-X., Tang, Z-Y., Liu, K-D., Xue, Q., Gao, D-M., Yu, Y-Q., Zhou, X-D., Ma, Z-C. Metastatic models of human liver cancer in nude mice orthotopically constructed by using histologically intact patient specimens. *J. Cancer Res. Clin. Oncol.* 122, 397-402, 1996. [PDF]
3. Rashidi, B., An, Z., Sun, F-X, Li, X-M., Tang, Z.Y., Moossa, A.R., and Hoffman, R.M. Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice. *Int. J. Cancer* 91, 231-235, 2001. [PDF]
4. Wu, M., Mazarchuk, R., Chaudhary, N.D., Sperryak, J., Veith, J., Pera, P., Greco, W., Hoffman, R.M., Kobayashi, T., and Bernacki, R.J. High Resolution Magnetic Resonance Imaging of the Efficacy of the Cytosine Analogue 1-[2-C-Cyano-2-deoxy-b-D-arabino-pentofuranosyl]-N4 - palmitoyl Cytosine (CS-682) in a Liver-Metastasis Athymic Nude Mouse Model. *Cancer Res.* 63, 2477-2482, 2003. [PDF]
5. Suetsugu, S., Osawa, Y., Nagaki, M., Moriwaki, H., Saji, S., Bouvet, M., and Hoffman, R.M. Simultaneous color-coded imaging to distinguish cancer stem-like and non-stem cells in the same tumor. *J. Cell. Biochem.* 111, 1035-1041, 2010.
6. Wang, M., Zhang, X., Xiong, X., Yang, Z., Sun, Y., Yang, Z., Hoffman, R.M., and Liu, Y. Efficacy of the Chinese Traditional Medicinal Herb *Celastrus orbiculatus* Thunb on human hepatocellular carcinoma in an orthotopic fluorescent nude mouse model. *Anticancer Res.* 32, 1213-1220, 2012.
7. Momiyama, M., Kumamoto, T., Suetsugu, A., Kishimoto, H., Chishima, T., Tanaka, K., Akiyama, H., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Major liver resection stimulates stromal recruitment and metastasis compared with repeated minor resection. *J. Surg. Res.* 178, 280-287, 2012.
8. He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S.E., Jepsen, K., Frazer, K.A., Harismendy, O., Hatziapostolou, M., Iliopoulos, D., Suetsugu, A., Hoffman, R.M., Tateishi, R., Koike, K., Karin, M. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling. *Cell* 155, 384-396, 2013.

AntiCancer Inc.

MetaMouse

Cervix

1. Murata, T., Mizushima, H., Chinen, I., Moribe, H., Yagi, S., Hoffman, R.M., Kimura, T., Yoshino, K., Ueda, Y., Enomoto, T., and Mekada, E. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. *Cancer Res.* 71, 6633-6642, 2011.
2. Hiroshima, Y., Zhang, Y., Zhang, M., Maawy, A., Mii, S., Yamamoto, M., Uehara, F., Miwa, S., Yano, S., Murakami, T., Momiyama, M., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Murata, T., Endo, I., and Hoffman, R.M. Establishment of a patient-derived orthotopic xenograph (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. *PLOS ONE* **10**, e0117417, 2015.
3. Hiroshima, Y., Zhang, Y., Zhao, M., Zhang, N., Murakami, T., Maawy, A., Mii, S., Uehara, F., Yamamoto, M., Miwa, S., Yano, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R in combination with Trastuzumab eradicates HER-2-positive cervical cancer cells in patient-derived mouse models. *PLoS One* **10**, e0120358, 2015.
4. Murakami, T., Murata, T., Kawaguchi, K., Kiyuna, T., Igarashi, K., Hwang, H.K., Hiroshima, Y., Hozumi, C., Komatsu, S., Kikuchi, T., Lwin, T.M., DeLong, J.C., Miyake, K., Zhang, Y., Tanaka, K., Bouvet, M., Endo, I., Hoffman, R.M. Cervical cancer patient-derived orthotopic xenograft (PDOX) is sensitive to cisplatin and resistant to nab-paclitaxel. *Anticancer Research* **37**, 61-66, 2017.
5. Miyake K, Murata T, Murakami T, Zhao M, Kiyuna T, Kawaguchi K, Igarashi K, Miyake M, Lwin TM, Hozumi C, Komatsu S, Kikuchi T, Bouvet M, Shimoya K, Singh SR, Endo I, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. *Arch Gynecol Obstet.* 299(6):1683-1690. 2019.

Ovarian

1. Fu, X., and Hoffman, R.M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. *Anticancer Res.* 13, 283-286, 1993.[PDF]
2. Astoul, P., Colt, H.G., Wang, X., and Hoffman, R.M. Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. *Anticancer Res.* 13, 1999-2002, 1993. [PDF]
3. Kiguchi, K., Kubota, T., Aoki, D., Udagawa, Y., Yamanouchi, S., Saga, M., Amemiya, A., Nozawa, S., Moossa, A.R., and Hoffman, R.M. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. *Clinical & Experimental Metastasis* 16, 751-756, 1998. [PDF]

AntiCancer Inc.

MetaMouse

4. Steinkamp, M.P., Winner, K.K., Davies, S., Muller, C., Zhang, Y., Hoffman, R.M., Shirinifard, A., Moses, M., Jiang, Y., and Wilson, B.S. Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models. *Frontiers in Oncology*, published online, 2013. DOI: 10.3399/fonc.2013.00097.
5. Lee, S.E., Bairstow, S.F., Werling, J.O., Chaubal, M.V., Lin, L., Murphy, M.A., Diorio, J. P., Gass, J., Rabinow, B., Wang, X., Zhang, Y., Yang, Z., and Hoffman, R.M. Paclitaxel nanosuspensions for targeted chemotherapy □ nanosuspension preparation, characterization, and use. *Pharm. Dev. Technol.* 19, 438-453, 2014.

Sarcoma

1. Yamamoto, N., Yang, M., Jiang, P., Xu, M., Tsuchiya, H., Tomita, K., Moossa, A.R., and Hoffman, R.M. Real-time imaging of individual color-coded metastatic colonies in vivo. *Clin. Exp. Metastasis* 20(7), 633-638, 2003.[PDF]
2. Kimura, H., Tome, Y., Momiyama, M., Hayashi, K., Tsuchiya, H., Bouvet, M., and Hoffman, R.M. Imaging the inhibition by anti-b1 integrin antibody of lung seeding of single osteosarcoma cells in live mice. *Int. J. Cancer* 131, 2027-2033, 2012.
3. Uehara, F., Tome, Y., Yano, S., Miwa, S., Mii, S., Hiroshima, Y., Bouvet, M., Maehara, H., Kanaya, F., and Hoffman, R.M. A color-coded imaging model of the interaction of αv integrin-GFP expressed in osteosarcoma cells and RFP expressing blood vessels in Gelfoam \exists vascularized in vivo. *Anticancer Res.* 33, 1361-1366, 2013.
4. Tome, Y., Sugimoto, N., Yano, S., Momiyama, M., Mii, S., Maehara, H., Bouvet, M., Tsuchiya, H., Kanaya, F., and Hoffman, R.M. Real-time imaging of αv integrin molecular dynamics in osteosarcoma cells in vitro and in vivo. *Anticancer Research* 33, 3021-3025.
5. Tome, Y., Kimura, H., Maehara, H., Sugimoto, N., Bouvet, M., Tsuchiya, H., Kanaya, F., Hoffman, R.M. High lung-metastatic variant of human osteosarcoma cells, selected by passage of lung metastasis in nude mice, is associated with increased expression of $\alpha v \beta 3$ integrin. *Anticancer Research* 33, 3623-3628, 2013
6. Miwa, S., Yano, S., Tome, Y., Sugimoto, N., Hiroshima, Y., Uehara, F., Mii, S., Kimura, H., Hayashi, K., Efimova, E.V., Fujiwara, T., Tsuchiya, H., and Hoffman, R.M. Dynamic color-coded fluorescence imaging of the cell-cycle phase, mitosis, and apoptosis demonstrates how caffeine modulates cisplatin efficacy. *J. Cell. Biochem.* 114, 2454-2460, 2013.
7. Kimura, H., Tome, Y., Momiyama, M., Hayashi, K., Tsuchiya, H., Bouvet, M., and Hoffman, R.M. Imaging the inhibition by anti-b1 integrin antibody of lung seeding of single osteosarcoma cells in live mice. *Int. J. Cancer* 131, 2027-2033, 2012. DOI: 10.1002/ijc.27475.
8. Uehara, F., Tome, Y., Yano, S., Miwa, S., Mii, S., Hiroshima, Y., Bouvet, M., Maehara, H., Kanaya, F., and Hoffman, R.M. A color-coded imaging model of the interaction of αv integrin-GFP

AntiCancer Inc.

MetaMouse

- expressed in osteosarcoma cells and RFP expressing blood vessels in Gelfoam \Rightarrow vascularized in vivo. *Anticancer Res.* 33, 1361-1366, 2013.
9. Wolf, K., te Lindert, M., Krause, M., Alexander, S., te Riet, J., Willis, A.L., Hoffman, R.M., Figdor, C.G., Weiss, S.J., and Friedl, P. Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force. *J. Cell. Biol.* 201, 1069-1084, 2013.
 10. Tome, Y., Sugimoto, N., Yano, S., Momiyama, M., Mii, S., Maehara, H., Bouvet, M., Tsuchiya, H., Kanaya, F., and Hoffman, R.M. Real-time imaging of αv integrin molecular dynamics in osteosarcoma cells in vitro and in vivo. *Anticancer Research* 33, 3021-3025.
 11. Hiroshima, Y., Zhang, Y., Zhang, N., Uehara, F., Maawy, A., Murakami, T., Mii, S., Yamamoto, M., Miwa, S., Yano, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. *Anticancer Research* **35**, 697-701, 2015.
 12. Hiroshima, Y., Zhao, M., Zhang, Y., Zhang, N., Maawy, A., Murakami, T., Mii, S., Uehara, F., Yamamoto, M., Miwa, S., Yano, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice. *PLoS One* **10**, e0134324, 2015.
 13. Murakami, T., DeLong, J., Eilber, F.C., Zhao, M., Zhang, Y., Zhang, N., Singh, A., Russell, T., Deng, S., Reynoso, J., Quan, C., Hiroshima, Y., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Chawla, S., Endo, I., and Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model. *Oncotarget* **7**, 12783-12790, 2016.
 14. Kiyuna, T., Murakami, T., Tome, Y., Kawaguchi, K., Igarashi, K., Zhang, Y., Zhao, M., Li, Y., Bouvet, M., Kanaya, F., Singh, A., Dry, S., Eilber, F.C., and Hoffman, R.M. High efficacy of tumor-targeting *Salmonella typhimurium* A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. *Oncotarget* **7**, 33046-33054, 2016.
 15. Murakami, T., Singh, A.S., Kiyuna, T., Dry, S.M., Li, Y., James, A.W., Igarashi, K., Kawaguchi, K., DeLong, J.C., Zhang, Y., Hiroshima, Y., Russell, T., Eckardt, M.A., Yanagawa, J., Federman, N., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Effective molecular targeting of *CDK4/6* and *IGF-1R* in a rare *FUS-ERG* fusion *CDKN2A*-deletion doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget* **7**, 47556-47564, 2016.

AntiCancer Inc.

MetaMouse

16. Kiyuna, T., Murakami, T., Tome, Y., Igarashi, K., Kawaguchi, K., Russell, T., Eckhardt, M.A., Crompton, J., Singh, A., Bernthal, N., Bukata, S., Federman, N., Kanaya, F., Eilber, F.C., and Hoffman, R.M. Labeling the stroma of a patient-derived orthotopic xenograft (PDOX) mouse models of undifferentiated pleomorphic soft-tissue sarcoma with red fluorescent protein for rapid non-invasive drug screening. *J. Cell. Biochem.* **118**, 361-365, 2017.
17. Murakami, T., Igarashi, K., Kawaguchi, K., Kiyuna, T., Zhang, Y., Zhao, M., Hiroshima, Y., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T., Federman, N., Singh, A., Elliott, I., Matsuyama, R., Chishima, T., Tanaka, K., Endo, I., Eilber, F.C., and Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R regresses an osteosarcoma in a patient-derived xenograph model resistant to a molecular-targeting drug. *Oncotarget* **8**, 8035-8042, 2017.
18. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. *Cell Cycle* **16**, 91-94, 2017.
19. Murakami, T., Li, S., Han, Q., Tan, Y., Kiyuna, T., Igarashi, K., Kawaguchi, K., Hwang, H.K., Miyake, K., Singh, A.S., Nelson, S.D., Dry, S.M., Li, Y., Hiroshima, Y., Lwin, T.M., DeLong, J.C., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget* **8**, 35630-35638, 2017.
20. Kawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Nelson, S.D., Dry, S.M., Li, Y., Russell, T.A., Singh, A.S., Chmielowski, B., Unno, M., Eilber, F.C., and Hoffman, R.M. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. *Cell Cycle* **16**, 1063-1069, 2017.
21. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T.A., Singh, A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Intra-arterial administration of tumor-targeting *Salmonella typhimurium* A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Cell Cycle* **16**, 1164-1170, 2017.
22. Murakami, T., Kiyuna, T., Kawaguchi, K., Igarashi, K., Singh A.S., Hiroshima, Y., Zhang Y., Zhao, M., Miyake, K., Nelson S.D., Dry, S.M., Li, Y., DeLong, J.C., Lwin, T.M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. *Cell Cycle* **16**, 1046-1052, 2017.
23. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Singh, A., Nelson, S.D., Dry,

AntiCancer Inc.

MetaMouse

- S.M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J. Cell. Biochem.* **118**, 2739-3743, 2017.
24. Kiyuna, T., Murakami, T., Tome, Y., Kawaguchi, K., Igarashi, K., Miyake, K., Kanaya, F., Singh, A., Eilber, F.C., and Hoffman, R.M. Analysis of stroma labeling during multiple passage of a sarcoma imageable patient-derived orthotopic xenograft (iPDOX) in red fluorescent protein transgenic nude mice. *J Cell. Biochem.* **118**, 3367-3371, 2017.
25. Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T.A., Singh, A.S., Tsuchiya, H., Elliott I., Eilber, F.C., and Hoffman, R.M. A patient-derived orthotopic xenograft (PDOX) mouse model of an cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. *Oncotarget* **8**, 62111-62119, 2017.
26. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget* **8**, 75874-75880, 2017.
27. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Yamamoto, N., Hayashi, K., Kimura, H., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Miwa, S., Odani, A., Eilber, F.C., Tsuchiya, H., Hoffman, R.M. A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). *Oncotarget* **8**, 63353-63359, 2017.
28. Miyake, K., Murakami, T., Kiyuna, T., Igarashi, K., Kawaguchi, K., Miyake, M., Li, Y., Nelson, S.D., Dry, S.M., Bouvet, M., Elliott, I.A., Russell, T.A., Singh, A.S., Eckardt, M.A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Endo, I., Eilber, F.C., Hoffman, R.M. The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a *FUS-ERG* fusion and CDKN2A deletion: Direction for third-line patient therapy. *Oncotarget* **8**, 103129-103136, 2017.
29. Igarashi, K., Kawaguchi, K., Li, S., Han, Q., Tan, Y., Murakami, T., Kiyuna, T., Miyake, K., Miyake, M., Singh, A.S., Eckhardt, M.A., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Singh, R.S., Eilber, F.C., Hoffman, R.M. Recombinant methioninase in combination with DOX overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. *Cancer Letters* **417**, 168-173, 2018.

AntiCancer Inc.

MetaMouse

30. Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyake, M., Li, S., Han, Q., Tan, Y., Zhao, M., Li, Y., Nelson, S.D., Dry, S.M., Singh, A.S., Elliott, I., Russell, T.A., Eckardt, M.A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: Decoy, trap and kill chemotherapy moves toward the clinic. *Cell Cycle* **17**, 801-809, 2018.
31. Miyake, K., Murakami, T., Kiyuna, T., Igarashi, K., Kawaguchi, K., Li, Y., Singh, A.S., Dry, S.M., Eckardt, M.A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Endo, I., Eilber, F.C., and Hoffman, R.M. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion for the patient-derived orthotopic xenograft (PDOX) nude mouse model. *J. Cell. Biochem.* **119**, 967-972, 2018.
32. Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyake, M., Li, Y., Nelson, S.D., Dry, S.M., Singh, A.S., Elliott, I., Russell, T.A., Eckhardt, M.A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. *Oncotarget* **9**, 7774-7781, 2018.
33. Igarashi, K., Li, S., Han, Q., Tan, Y., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Li, Y., Nelson, S.D., Dry, S.M., Singh, A.S., Elliott, I., Russell, T.A., Eckhardt, M.A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Growth of a doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. *J. Cell. Biochem.* **119(4)**, 3537-3544, 2018.
34. Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyake, M., Singh, A.S., Eckhardt, M.A., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma in patient-derived orthotopic xenograft (PDOX) nude-mouse models. *Biochem. Biophys. Res. Comm.* **497**, 1055-1061, 2018.
35. Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. *Cancer Chemother Pharmacol.* **83(6)**:1075-1082. 2019.
36. Higuchi T, Miyake K, Oshiro H, Sugisawa N, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Trabectedin and

AntiCancer Inc.

MetaMouse

- irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. *Biochem Biophys Res Commun.* 513(2):326-331. 2019.
37. Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh SR, Tsuchiya H, Hoffman RM. Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. *Tissue Cell.* 58:107-111. 2019.
38. Oshiro H, Tome Y, Kiyuna T, Miyake K, Kawaguchi K, Higuchi T, Miyake M, Zang Z, Razmjooei S, Barangi M, Wangsiricharoen S, Nelson SD, Li Y, Bouvet M, Singh SR, Kanaya F, Hoffman RM. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model. *Tissue Cell.* 58:17-23. 2019.
39. Miyake K, Higuchi T, Oshiro H, Zhang Z, Sugisawa N, Park JH, Razmjooei S, Katsuya Y, Barangi M, Li Y, Nelson SD, Murakami T, Homma Y, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM. The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. *Biomed Pharmacother.* 11;117, 2019. [Epub ahead of print]
40. Miyake, K., Kiyuna, T., Miyake, M., Kawaguchi, K., Yoon, S.N., Zhang, Z., Igarashi, K., Razmjooei, S., Wangsiricharoen, S., Murakami, T., Li, Y., Nelson, S.D., Russell, T.A., Singh, A.S., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Singh, S.R., Endo, I., Eilber, F.C., Hoffman, R.M. Patient-derived orthotopic xenograft models of cancer of unknown primary precisely distinguish chemotherapy while tumor-targeting *S. typhimurium AI-R* is superior to first-line chemotherapy. *Signal Transduction and Targeted Therapy* **3**, 12, 2018.
41. Kawaguchi, K., Igarashi, K., Kiyuna, T., Miyake, K., Miyake, M., Murakami, T., Chmielowski, B., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., Hoffman, R.M. Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. *Cell Cycle* **17**, 627-633, 2018.
42. Igarashi, K., Kawaguchi, K., Li, S., Han, Q., Tan, Y., Gainor, E., Kiyuna, T., Miyake, K., Miyake, M., Singh, A.S., Eckhardt, M.A., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Higuchi, T., Oshiro, H., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget* **9**, 19263-19272, 2018.
43. Miyake, K., Kawaguchi, K., Kiyuna, T., Miyake, M., Igarashi, K., Zhang, Z., Murakami, T., Li, Y., Nelson, S.D., Elliott, I., Russell, T., Singh, A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chisima, T., Endo, I., Eilber, F.C., Hoffman, R.M. Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 in a patient-

AntiCancer Inc.

MetaMouse

- derived orthotopic xenograft (PDOX) nude mouse model. *Cell Cycle* **17**, 722-727, 2018.
44. Kiyuna T, Tome Y, Murakami T, Zhao M, Miyake K, Igarashi K, Kawaguchi K, Miyake M, Oshiro H, Higuchi T, Li Y, Dry SM, Nelson SD, Russell TA, Eckardt MA, Singh AS, Kanaya F, Eilber FC, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. *J Cell Biochem.* **119**, 7827-7833, 2018.
 45. Miyake K, Kawaguchi K, Miyake M, Zhao M, Kiyuna T, Igarashi K, Zhang Z, Murakami T, Li Y, Nelson SD, Bouvet M, Elliott I, Russell TA, Singh AS, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Endo I, Eilber FC, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. *Heliyon* **4**, e00643. 2018.
 46. Kawaguchi K, Igarashi K, Miyake K, Kiyuna T, Miyake M, Singh AS, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Singh SR, Eilber FC, Hoffman RM. Patterns of Sensitivity to a Panel of Drugs are highly Individualized for Undifferentiated/Unclassified Soft Tissue Sarcoma (USTS) in Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Models. *J Drug Target* **19**, 1-25. 2018.
 47. Kiyuna T, Murakami T, Tome Y, Igarashi K, Kawaguchi K, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Russell TA, Singh SR, Kanaya F, Eilber FC, Hoffman RM. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. *Tissue and Cell* **53**, 30-36. 2018.
 48. Kiyuna T, Tome Y, Murakami T, Kawaguchi K, Igarashi K, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Russell TA, Elliott I, Singh SR, Kanaya F, Eilber FC, and Hoffman RM. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. *BMC Cancer* **18**, 840, 2018.
 49. Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM. *Tissue and Cell* **54**, 144-149, 2018.
 50. Kiyuna T, Tome Y, Murakami T, Miyake M, Sugisawa N, Zhang Z, Razmjooei S, Wangsiricharoen S, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Eckardt MA, Singh AS, Chawla S, Kanaya F, Eilber FC, Singh SR, Zhao M, Hoffman RM. A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting *Salmonella typhimurium*

AntiCancer Inc.

MetaMouse

- A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model). *Biochem. Biophys. Res. Comm.*, 2018.
51. Higuchi T, Kawaguchi K, Miyake K, Han Q, Tan Y, Oshiro H, Sugisawa N., Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla ST, Singh AR, Eilber FC, Singh SR, Tsuchiya H, and Hoffman RM. Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma patient-derived orthotopic xenograft (PDOX) mouse model. *Anticancer Res.* **38**, 5639-5644, 2018.
 52. Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyaki M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh AS, Chmielowski B, Nelson SD, Russell TA, Eckardt MA, Dry SM, Li Y, Singh SR, Chawla SP, Eilber FC, Tsuchiya H, Hoffman RM. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. *Biochem Biophys Res Commun.* 506(4):912-917, 2018.
 53. Oshiro H, Kiyuna T, Tome Y, Miyake K, Kawaguchi K, Higuchi T, Miyake M, Zhang Z, Razmjooei S, Barangi M, Wangsiricharoen S, Nelson SD, Li Y, Bouvet M, Singh SR, Kanaya F, Hoffman RM. Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein. *Anticancer Res.*39(1):81-85, 2019.
 54. Higuchi T, Kawaguchi K, Miyake K, Oshiro H, Zhang Z, Razmjooei S, Wangsiricharoen S, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Nelson SD, Dry SM, Li Y, Chawla SP, Eilber FC, Singh SR, Tsuchiya H, Hoffman RM. The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Biomed Pharmacother.* 111:835-840, 2019.
 55. Miyake K, Kiyuna T, Miyake M, Kawaguchi K, Zhang Z, Wangsiricharoen S, Razmjooei S, Oshiro H, Higuchi T, Li Y, Nelson SD, Murakami T, Hiroshima Y, Kumamoto T, Matsuyama R, Bouvet M, Singh SR, Chawla SP, Endo I, Hoffman RM. Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. *Biochem Biophys Res Commun.* 9;509(4):1041-1046. 2019.
 56. Miyake K, Kiyuna T, Li S, Han Q, Tan Y, Zhao M, Oshiro H, Kawaguchi K, Higuchi T, Zhang Z, Razmjooei S, Barangi M, Wangsiricharoen S, Murakami T, Singh AS, Li Y, Nelson SD, Eilber FC, Bouvet M, Hiroshima Y, Chishima T, Matsuyama R, Singh SR, Endo I, Hoffman RM. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. *Chemotherapy.*63(5):278-283, 2018.
 57. Miyake K, Kiyuna T, Kawaguchi K, Higuchi T, Oshiro H, Zhang Z, Wangsiricharoen S, Razmjooei S, Li Y, Nelson SD, Murakami T, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP,

AntiCancer Inc.

MetaMouse

- Singh SR, Endo I, Hoffman RM. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *Cancer Chemother Pharmacol.* 2019 Feb 13. [Epub ahead of print]
58. Zhang Z, Hu K, Kiyuna T, Miyake K, Kawaguchi K, Igarashi K, Nelson SD, Li Y, Singh SR, Hoffman RM. A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. *Pharmacol Res.* 2019 Feb 23. [Epub ahead of print]
59. 109. Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. *Cancer Lett.* 10;451:122-127, 2019.
60. Higuchi T, Oshiro H, Miyake K et al. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. *Anticancer Res* 2019; 39: 4653-4657.
61. Oshiro H, Tome Y, Kiyuna T et al. Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model. *Anticancer Res* 2019; 39: 4667-4671.
62. Kiyuna T, Tome Y, Miyake K et al. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. *Anticancer Res* 2019; 39: 4775-4779.
63. Higuchi T, Sugisawa N, Miyake K et al. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. *Anticancer Res* 2019; 39: 4781-4786.
64. Higuchi T, Sugisawa N, Miyake K et al. Pioglitazone, an agonist of PPARgamma, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. *Biomed Pharmacother* 2019; 118: 109356.
65. Igarashi K, Kawaguchi K, Murakami T, Miyake K, Kiyuna T, Miyake M, Hiroshima Y, Higuchi T, Oshiro H, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Singh SR, Tsuchiya H, Hoffman RM. Patient-derived orthotopic xenograft models of sarcoma. *Cancer Lett.* 2020 Jan 28;469:332-339. doi: 10.1016/j.canlet.2019.10.028.
66. Higuchi T, Sugisawa N, Yamamoto J, Oshiro H, Han Q, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Tan Y, Kuchipudi S, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. *Cancer Chemother Pharmacol.* 2020 Feb;85(2):285-291. doi: 10.1007/s00280-019-03986-0.

AntiCancer Inc.

MetaMouse

67. Higuchi T, Han Q, Miyake K, Oshiro H, Sugisawa N, Tan Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. *Biochem Biophys Res Commun.* 2020 Feb 26;523(1):135-139. doi: 10.1016/j.bbrc.2019.12.024.
68. Higuchi T, Yamamoto J, Sugisawa N, Tashiro Y, Nishino H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. PPAR γ Agonist Pioglitazone in Combination With Cisplatin Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. *Cancer Genomics Proteomics.* 2020 Jan-Feb;17(1):35-40. doi: 10.21873/cgp.20165.
69. Igarashi K, Kawaguchi K, Zhao M, Kiyuna T, Miyake K, Miyake M, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh SR, Tsuchiya H, Hoffman RM. Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. *Transl Oncol.* 2020 Feb;13(2):393-400. doi: 10.1016/j.tranon.2019.10.005.

Bone cancer and metastasis

1. Yang, M., Hasegawa, S., Jiang, P., Wang, X., Tan, Y., Chishima, T., Shimada, H., Moossa, A.R., and Hoffman, R.M. Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. *Cancer Research* 58, 4217-4221, 1998
2. Yang, M., Jiang, P., Sun, F.X., Hasegawa, S., Baranov, E., Chishima, T., Shimada, H., Moossa, A.R., and Hoffman, R.M. A fluorescent orthotopic bone metastasis model of human prostate cancer. *Cancer Research* 59, 781-786, 1999
3. Yang, M., Jiang, P., An, Z., Baranov, E., Li, L., Hasegawa, S., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. Genetically fluorescent melanoma bone and organ metastasis models. *Clinical Cancer Research* 5, 3549-3559, 1999
4. Yang, M., Baranov, E., Jiang, P., Sun, F-X., Li, X-M., Li, L., Hasegawa, S., Bouvet, M., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A.R., Penman, S., Hoffman, R.M. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. *Proc. Natl. Acad. Sci. USA* 97, 1206-1211, 2000
5. Deftos, L.J., Barken, I., Burton, D.W., Hoffman, R.M., and Geller, J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. *Biochem. Biophys. Res. Commun.* 327, 468-472, 2005
6. Burton, D.W., Geller, J., Yang, M., Jiang, P., Barken, I., Hastings, R.H., Hoffman, R.M., and Deftos, L.J. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. *The Prostate* 62, 275-281, 2005.
7. Yang, M., Burton, D.W., Geller, J., Hillemonds, D., Hastings, R.H., Deftos, L.J., and Hoffman,

AntiCancer Inc.

MetaMouse

- R.M. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. *Clinical Cancer Research* 12, 2602-2606, 2006
- Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Kishimoto, H., Bouvet, M., and Hoffman, R.M. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle* 8, 870-875, 2009.
 - Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., and Hoffman, R.M. Cancer metastasis directly eradicated by targeted therapy with a modified *Salmonella typhimurium*. *J. Cell. Biochem.* 106, 992-998, 2009.
 - Tome, Y., Tsuchiya, H., Hayashi, K., Yamauchi, K., Sugimoto, N., Kanaya, F., Tomita, K., and Hoffman, R.M. In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential. *J. Cell. Biochem.* 108, 362-367, 2009. DOI: 10.1002/jcb.22259.
 - Ongkeko, W.M., Burton, D., Kiang, A., Abhold, E., Kuo, S.Z., Rahimy, E., Yang, M., Hoffman, R.M., Wang-Rodriguez, J., Deftos, L.J. Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer. *PLoS One* 9, e85803, 2014.

Bladder

- Fu, X., Theodorescu, D., Kerbel, R.S., and Hoffman, R.M. Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. *Int. J. Cancer* 49, 938-939, 1991.
- Fu, X., and Hoffman, R.M. Human RT-4 bladder carcinoma is highly metastatic in nude mice and comparable to ras-H-transformed RT-4 when orthotopically onplanted as histologically intact tissue. *Int. J. Cancer* 51, 989-991, 1992.
- Chang, S-G., Kim, J.I., Jung, J-C., Rho, Y-S., Lee, K-T., An, Z., Wang, X., and Hoffman, R.M. Antimetastatic activity of the new platinum analog in a metastatic model of human bladder cancer. *Anticancer Res.* 17, 3239-3242, 1997.
- Zhou, J-H., Rosser, C.J., Tanaka, M., Yang, M., Baranov, E., Hoffman, R.M., Benedict, W.F. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. *Cancer Gene Therapy* 9, 681-686, 2002.

Prostate

- Fu, X., Herrera, H., and Hoffman, R.M. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histologically intact tissue. *Int. J. Cancer* 52, 987-990, 1992. [PDF]
- An, Z., Wang, X., Geller, J., Moossa, A.R., and Hoffman, R.M. Surgical orthotopic

AntiCancer Inc.

MetaMouse

- implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice. *The Prostate* 34, 169-174, 1998.
3. Yang, M., Jiang, P., Sun, F.X., Hasegawa, S., Baranov, E., Chishima, T., Shimada, H., Moossa, A.R., and Hoffman, R.M. A fluorescent orthotopic bone metastasis model of human prostate cancer. *Cancer Res.* 59, 781-786, 1999. [PDF]
 4. Wang, X., An, Z., Geller, J., and Hoffman, R.M. High malignancy orthotopic nude mouse model of human prostate cancer LNCaP. *The Prostate* 39, 182-186, 1999.
 5. Glinskii, A.B., Smith, B.A., Jiang, P., Li, X-M., Yang, M., Hoffman, R.M., Glinsky, G.V. Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models. *Cancer Res.* 63, 4239-4243, 2003.[PDF]
 6. Glinsky, G.V., Glinskii, A.B., Stephenson A.J., Hoffman, R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. *J. Clin. Invest.* 113, 913-923, 2004 [PDF]
 7. Yang, M., Jiang, P., Yamamoto, N., Li, L., Geller, J., Moossa, A.R., and Hoffman, R.M. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. *The Prostate* 62, 374-379, 2005. DOI #10.1002/pros.20125. [PDF]
 8. Burton, D.W., Geller, J., Yang, M., Jiang, P., Barken, I., Hastings, R.H., Hoffman, R.M., and Deftos, L.J. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. *The Prostate* 62, 275-281, 2005. DOI: 10.1002/pros.2014. [PDF]
 9. Deftos, L.J., Barken, I., Burton, D.W., Hoffman, R.M., and Geller, J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. *Biochem. Biophys. Res. Commun.* 327, 468-472, 2005. [PDF]
 10. Berezovskaya, O., Schimmer, A.D., Glinskii, A.B., Pinilla, C., Hoffman, R.M., Reed, J.C., and Glinsky, G.V. Increased expression of apoptosis inhibitor protein XIAP contributes to resistance to anoikis of human prostate cancer metastasis precursor cells. *Cancer Research* 65, 2378-2386, 2005. [PDF]
 11. Glinsky, G.V., Glinski, A.B., Berezovskaya, O., Smith, B.A., Jiang, P., Li, X-M., Yang, M., Hoffman, R.M. Dual color-coded imaging of viable circulating prostate carcinoma cells reveals genetic exchange between tumor cells in vivo, contributing to highly metastatic phenotypes. *Cell Cycle* 5, 191-197, 2006.
 12. Yang, M., Burton, D.W., Geller, J., Hillegonds, D., Hastings, R.H., Deftos, L.J., and Hoffman, R.M. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. *Clinical Cancer Research* 12, 2602-2606, 2006. [PDF]
 13. Berezovska, O.P., Glinskii, A.B., Yang, Z., Li, X.M., Hoffman, R.M., and Glinsky, G.V. Essential role for activation of the Polycomb Group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. *Cell Cycle* 5, 1886-1901, 2006. [PDF]
 14. Hoffman, R.M. Orthotopic metastatic mouse models of prostate cancer. In: *Metastasis of Prostate*

AntiCancer Inc.

MetaMouse

- Cancer, pp. 143-169. Ablin, R.J. and Mason, M.D., eds. Kluwer Academic Publishers, 2007.[PDF]
15. Zhang, Q., Yang, M., Shen, J., Gerhold, L.M., Hoffman, R.M., Xing, H.R. The role of the intravascular microenvironment in spontaneous metastasis development. *International Journal of Cancer* 126, 2534-2541, 2010.
 16. Kolostova, K., Pinterova, D., Hoffman, R.M., and Bobek, V. Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. *Anticancer Res.* 31, 1535-1539, 2011.
 17. Menen, R.S., Pinney, E., Kolostova, K., Bobek, V., Suetsugu, A., Zhang, N., Bouvet, M., and Hoffman, R.M. A rapid imageable in vivometastasis assay for circulating tumor cells. *Anticancer Res.* 31, 3125-3128, 2011.
 18. Menen, R., Pinney, E., Hassanein, M.K., Kolostova, K., Bobek, V., Suetsugu, A., Zhang, N., Bouvet, M., and Hoffman, R.M. Inhibition of metastasis of circulating human prostate cancer cells in the chick embryo by an extracellular matrix produced by foreskin fibroblasts in culture. *Anticancer Research* 32, 1573-1577, 2012.
 19. Menen, R., Zhao, M., Zhang, L., Hassanein, M.K., Bobek, V., Kolostova, K., Bouvet, M., and Hoffman, R.M. Comparative chemosensitivity of circulating human prostate cancer cells and primary cancer cells. *Anticancer Research* 32, 2881-2884, 2012.
 20. Ongkeko, W.M., Burton, D., Kiang, A., Abhold, E., Kuo, S.Z., Rahimy, E., Yang, M., Hoffman, R.M., Wang-Rodriguez, J., Deftos, L.J. Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer. *PLoS One* 9, e85803, 2014.

Kidney

1. An, Z., Jiang, P., Wang, X., Moossa, A.R., and Hoffman, R.M. Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: Benefits of fragment implantation compared to cell-suspension injection. *Clinical & Experimental Metastasis* 17, 265-270, 1999. [PDF]

Lymphoma

1. Schmitt, C.A., Fridman, J.S., Yang, M., Baranov, E., Hoffman, R.M. and Lowe, S.W. Dissecting p53 tumor suppressor functions in vivo. *Cancer Cell* 1, 289-298, 2002.
2. Schmitt, C.A., Yang, M., Fridman, J.S., Baranov, E., Hoffman, R.M., and Lowe, S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell* 109, 335-346, 2002.

Melanoma

AntiCancer Inc.

MetaMouse

1. Yang, M., Jiang, P., An, Z., Baranov, E., Li, L., Hasegawa, S., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. Genetically fluorescent melanoma bone and organ metastasis models. *Clinical Cancer Research* 5, 3549-3559, 1999. [PDF]
2. Yang, M., Baranov, E., Jiang, P., Sun, F-X., Li, X-M., Li, L., Hasegawa, S., Bouvet, M., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A.R., Penman, S., Hoffman, R.M. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. *Proc. Natl. Acad. Sci. USA* 97, 1206-1211, 2000. [PDF]
3. Yang, M., Li, L., Jiang, P., Moossa, A.R., Penman, S., and Hoffman, R.M. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. *Proc. Natl. Acad. Sci. USA* 100, 14259-14262, 2003. [PDF]
4. Amoh, Y., Li, L., Yang, M., Jiang, P., Moossa, A.R., Katsuoka, K., and Hoffman, R.M. Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. *Cancer Res.* 65, 2337-2343. 2005.[PDF]
5. Zhang, Q., Fan, H., Shen, J., Hoffman, R.M., and Xing, H.R. Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. *PLoS One* 5, e9712, 2010. DOI: 10.1371/journal.pone.0009712.
6. Tsai, M-H., Aki, R., Amoh, Y., Hoffman, R.M., Katsuoka, K., Kimura, H., Lee, C., and Chang, C-H. GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. *Anticancer Research* 30, 3291-3294, 2010.
7. Bobek, V., Kolostova, K., Pinterova, D., Kacprzak, G., Adamiak, J., Kolodziej, J., Boubelik, M., Kubecova, M., and Hoffman, R.M. A clinically-relevant, syngeneic model of spontaneous, high-metastatic B16 mouse melanoma. *Anticancer Research* 30, 4799-4804, 2010
8. Bobek, V., Kolostova, K., Pinterova, D., Boubelik, M., Gurlich, R., and Hoffman, R.M. Tail spontaneous metastatic mouse model: Comparison of metastatic potential of orthotopic and heterotopic models imaged by GFP and RFP protein. *In Vivo* 25, 849-852, 2011.
9. Binder, D.C., Engels, B., Arina, A., Yu, P., Stauch, J.M., Fu, Y-X, Karrison, T., Burnette, B., Idel, C., Zhao, M., Hoffman, R.M., Munn, D.H., Rowley, D.A., and Schreiber, H. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. *Cancer Immunol. Res.*, 1, 123-133, 2013.
10. Yamamoto, M., Zhao, M., Hiroshima, Y., Zhang, Y., Shurell, E., Eilber, F.C., Bouvet, M., Noda, M., Hoffman, R.M. Efficacy of tumor-targeting *Salmonella typhimurium* A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *PLoS One* 11, e0160882, 2016.
11. Kawaguchi, K., Murakami, T., Chmielowski, B., Igarashi, K., Kiyuna, T., Unno, M., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Eilber, F.C., and Hoffman, R.M. Vemurafenib-resistant BRAF-

AntiCancer Inc.

MetaMouse

- V600E mutated melanoma is regressed by MEK targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. *Oncotarget* **7**, 71737-71743, 2016.
12. Kawaguchi, K., Igarashi, K., Murakami, T., Chmiewloski, B., Kiyuna, T., Zhao, M., Zhang, Y., Singh, A., Unno, M., Nelson, S.D., Russell, T., Dry, S.M., Li, Y., Eilber, F.C., Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R combined with Temozolomide regresses malignant melanoma with a BRAF-V600 mutation in a patient-derived orthotopic xenograft (PDOX) model. *Oncotarget* **7**, 85929-85936, 2016.
 13. Kawaguchi, K., Igarashi, K., Murakami, T., Zhao, M., Zhang, Y., Chmielowski, B., Kiyuna, T., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Tumor-targeting *Salmonella typhimurium* A1-R sensitizes melanoma with a BRAF-V600E mutation to vemurafenib in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J. Cell. Biochem.* **118**, 2314-2319, 2017.
 14. Kawaguchi, K., Igarashi, K., Chmielowski, B., Murakami, T., Kiyuna, T., Zhao, M., Zhang, Y., Nelson, S.D., Russell, T.A., Dry, S.M., Singh, A.S., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. *Salmonella typhimurium* A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. *Cell Cycle* **16**, 1288–1294, 2017.
 15. Hoffman, R.M. Patient-derived orthotopic xenografts (PDOX) models of melanoma. Special Issue “Animal Models of Melanoma”, Slominski, A., Guest Editor. *Intl J. Mol. Sci.* **18**, 1875, 2017. DOI: 10.3390/ijms18091875
 16. Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Kiyuna, T., Miyake, Y., Murakami, T., Chmielowski, B., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma growth in a patient-derived orthotopic xenograft. *Oncotarget* **8**, 85516-85525, 2017.
 17. Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Miyake, K., Kiyuna, T., Miyake, M., Murakami, T., Chmielowski, S., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., Hoffman, R.M. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. *Oncotarget* **9**, 915-923, 2018.
 18. Kawaguchi K, Higuchi T, Li S, Han Q, Tan Y, Igarashi K, Zhao M, Miyake K, Kiyuna T, Miyake M, Oshiro H, Sugisawa N, Zhang Z, Razmjooei S, Wangsiricharoen S, Chmielowski B, Nelson, SD, Russell, TA, Dry SM, Li Y, Eckardt MA, Singh AS, Singh SR, Eilber FC, Unno M, Hoffman RM. Combination therapy of tumor-targeting *Salmonella typhimurium* A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. *Biochem. Biophys. Res. Comm.*, **503**, 3086-3092,2018.

AntiCancer Inc.

MetaMouse

19.

Multiple Myeloma

1. Mitsiades, C.S., Mitsiades, N.S., Bronson, R.T., Chauhan, D., Munshi, N., Treon, P.S., Maxwell, C.A., Pilarski, L., Hideshima, T., Hoffman, R.M. Fluorescent Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in vivo Model: Biological and Clinical Implications. *Cancer Research* 63, 6689-6696, 2003. [PDF].

Nasopharyngeal Carcinoma

1. Liu, T., Ding, Y., Xie, W., Li, Z., Bai, X., Li, X., Fang, W., Ren, C., Wang, S., Hoffman, R.M., and Yao, K. An imageable metastatic treatment model of nasopharyngeal carcinoma. *Clin. Cancer Res.* 13, 3960-3967, 2007.[PDF]

Head and Neck

1. Lee, S.E., Bairstow, S.F., Werling, J.O., Chaubal, M.V., Lin, L., Murphy, M.A., Diorio, J. P., Gass, J., Rabinow, B., Wang, X., Zhang, Y., Yang, Z., and Hoffman, R.M. Paclitaxel nanosuspensions for targeted chemotherapy □ nanosuspension preparation, characterization, and use. *Pharm. Dev. Technol.* 19, 438-453, 2014.

Thyroid

1. Tran Cao, H.S., Kaushal, S., Snyder, C.S., Ongkeko, W.M., Hoffman, R.M., and Bouvet, M. Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer. *Anticancer Research* 30, 4415-4422, 2010.

TCM

1. Wang, M., Zhang, X., Xiong, X., Yang, Z., Sun, Y., Yang, Z., Hoffman, R.M., and Liu, Y. Efficacy of the Chinese Traditional Medicinal Herb *Celastrus orbiculatus* Thunb on human hepatocellular carcinoma in an orthotopic fluorescent nude mouse model. *Anticancer Res.* 32, 1213-1220, 2012.
2. Hu, M., Zhao, M., An, C., Yang, M., Zhang, Y., Suetsugu, A., Tome, Y., Yano, S., Fu, Y., Hoffman, R.M., and Hu, K. Real-time imaging of induction of apoptosis of human breast cancer cells by the traditional Chinese medicine herb *Tubeimu*. *Anticancer Res.* 32, 2509-2514, 2012.

Gene Therapy

1. Miki, K., Xu, M., An, Z., Wang, X., Yang, M., Al-Refaie, W., Sun, X., Baranov, E., Tan, Y.,

AntiCancer Inc.

MetaMouse

- Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. *Cancer Gene Therapy* 7, 332-338, 2000. . [PDF]
2. Miki, K., Al-Refaie, W., Xu, M., Jiang, P., Tan, Y., Bouvet, M., Zhao, M., Gupta, A., Chishima, T., Shimada, H., Makuuchi, M., Moossa, A.R., and Hoffman, R.M. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. *Cancer Res.* 60, 2696-2702, 2000.[PDF]
 3. Hasegawa, S., Yang, M., Chishima, T., Shimada, H., Moossa, A.R., Hoffman, R.M. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. *Cancer Gene Therapy* 7, 1336-1340, 2000. [PDF]
 4. Djeha, A.H., Thomson, T.A., Leung, H., Searle, P.F., Young, L.S., Kerr, D.J., Harris, P.A., Mountain, A., and Wrighton, C.J. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. *Molecular Therapy* 3, 233-240, 2001. [PDF]
 5. Chen, C.T., Lin, J., Li, Q., Phipps, S.S., Jakubczak, J.L., Stewart, D.A., Skripchenko, Y., Forry-Schaudies, S., Wood, J., Schnell, C., and Hallenbeck, P.L. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secreted endostatin. *Human Gene Therapy* 11, 1983-1996, 2000. [PDF]
 6. Miki, K, Xu, M., Gupta, A., Ba, Y., Tan, Y., Al-Refaie, W., Bouvet, M., Makuuchi, M., Moossa, A.R., and Hoffman, R.M. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. *Cancer Research* 61, 6805-6810, 2001. [PDF]
 7. Kamiyama, M., Ichikawa, Y., Ishikawa, T., Chishima, T., Hasegawa, S., Hamaguchi, Y., Nagashima, Y., Miyagi, Y., Mitsuhashi, M., Hyndman, D., Hoffman, R.M., Ohki, S., and Shimada, H. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. *Cancer Gene Therapy* 9, 197-201, 2002. [PDF]
 8. Pirocanac, E.C., Nassirpour, R., Yang, M., Wang, J-W., Nardin, S.R., Gu, J., Fang, B., Moossa, A.R., Hoffman, R.M., and Bouvet, M. Bax-induction gene therapy of pancreatic cancer. *J. Surg. Res.* 106, 346-351, 2002. [PDF]
 9. Hoffman, R.M. Immune reactions in skin and hair follicle gene therapy. *Molecular Therapy* 7, 294-295, 2003.
 10. Katz, M.H., Spivak, D.E., Takimoto, S., Fang, B., Burton, D.W., Moosa, A.R., Hoffman, R.M., Bouvet, M. Gene Therapy of Pancreatic Cancer With Green Fluorescent Protein and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Gene Expression Driven by a Human Telomerase Reverse Transcriptase Promoter. *Annals of Surgical Oncology*, 10(7): 762-772, 2003. [PDF]

AntiCancer Inc.

MetaMouse

Drug Discovery

1. Furukawa, T., Kubota, T., Watanabe, M., Kuo, T.H., Kase, S., Saikawa, Y., Tanino, H., Teramoto, T., Ishibiki, K., Kitajima, M., and Hoffman, R.M. Immunochemotherapy prevents human colon cancer metastasis after orthotopic onplantation of histologically-intact tumor tissue in nude mice. *Anticancer Res.* 13, 287-291, 1993.
2. Furukawa, T., Kubota, T., Watanabe, M., Kuo, T-H., Kitajima, M., and Hoffman, R.M. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. *Int. J. Cancer* 54, 397-401, 1993.
3. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., and Hoffman, R.M. A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. *Cancer Res.* 53, 3070-3072, 1993.
4. Kubota, T., Inoue, S., Furukawa, T., Ishibiki, K., Kitajima, M., Kawamura, E., and Hoffman, R.M. Similarity of Serum - Tumor Pharmacokinetics of Antitumor Agents in Man and Nude Mice. *Anticancer Res.* 13, 1481-1484, 1993.
5. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J., and Hoffman, R.M. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. *Cancer Res.* 54, 4726-4728, 1994.
6. Murray, G., Duncan, M., O'Neill, P., Melvin, W., Fothergill, J. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. *Nature Medicine* 2, 461-2, 1996.
7. An, Z., Wang, X., Astoul, P., Danays, T., Moossa, A.R., and Hoffman, R.M. Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. *Anticancer Res.* 16, 2545-2551, 1996.
8. Olbina, G., Cieslak, D., Ruzdijic, S., Esler, C., An, Z., Wang, X., Hoffman, R., Seifert, W., and Pietrzowski, Z. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. *Anticancer Res.* 16, 3525-3530, 1996.
9. An, Z., Wang, X., Willmott, N., Chander, S.K., Tickle, S., Docherty, A.J., Mountain, A., Millican, A.T., Morphy, R., Porter, J.R., Epemolu, R.O., Kubota, T., Moossa, A.R., and Hoffman, R.M. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. *Clinical & Experimental Metastasis* 15, 184-195, 1997.
10. Inada, T., Ichikawa, A., Kubota, T., Ogata, Y., Moossa, A.R., and Hoffman, R.M. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. *Anticancer Res.* 17, 1965-1971, 1997.
11. Tomikawa, M., Kubota, T., Matsuzaki, S.W., Takahasi, S., Kitajima, M., Moossa, A.R., and Hoffman, R.M. Mitomycin C and cisplatin increase survival in a human pancreatic cancer

AntiCancer Inc.

MetaMouse

- metastatic model. *Anticancer Res.* 17, 3623-3626, 1997.
12. Chang, S-G., Kim, J.I., Jung, J-C., Rho, Y-S., Lee, K-T., An, Z., Wang, X., and Hoffman, R.M. Antimetastatic activity of the new platinum analog {Pt(cis-dach)(DPPE) $\bar{7}$ 2NO₃} in a metastatic model of human bladder cancer. *Anticancer Res.* 17, 3239-3242, 1997.
 13. Tomikawa, M., Kubota, T., Matsuzaki, S.W., Takahasi, S., Kitajima, M., Moossa, A.R., and Hoffman, R.M. Mitomycin C and cisplatin increase survival in a human pancreatic cancer metastatic model. *Anticancer Res.* 17, 3623-3626, 1997.
 14. Sasson, A.R., Gamagami, R., An, Z., Wang, X., Moossa, A.R., and Hoffman, R.M. Cimetidine: an inhibitor or promoter of tumor growth? *International Journal of Cancer* 81, 835-838, 1999.
 15. Rho, Y-S., Lee, K-T., Jung, J-C, Yoon, C., An, Z., Hoffman, R.M., and Chang, S-G. Efficacy of new platinum analog DPPE in an orthotopic nude mouse model of human colon cancer. *Anticancer Res.* 19, 157-162, 1999.
 16. Woessner, R., An, Z., Li, X-M., Hoffman, R.M., Dix, R., Bitonti, A. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and b-glucuronidase-activated prodrug (HMR 1826). *Anticancer Res.* 20, 2289-2296, 2000.
 17. Rashidi, B., An, Z., Sun, F-X., Moossa, A.R., and Hoffman, R.M. Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice. *Clinical Cancer Res.* 6, 2464-2468, 2000. [PDF]
 18. Rashidi, B., An, Z., Sun, F-X, Li, X-M., Tang, Z.Y., Moossa, A.R., and Hoffman, R.M. Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice. *Int. J. Cancer* 91, 231-235, 2001.[PDF]
 19. Lee, N.C., Bouvet, M., Nardin, S., Jiang, P., Baranov, E., Rashidi, B., Yang, M., Wang, X., Moossa, A.R., and Hoffman, R.M. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. *Clinical & Experimental Metastasis* 18, 379-384, 2001.[PDF]
 20. Ireson, C.R., Chander, S.K., Purohit, A., Perera, S., Newman, S.P., Parish, D., Leese, M.P., Smith, A.C., Potter, B.V. and Reed, M.J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo rodents. *Br. J. Cancer* 90, 932-937, 2004.
 21. Wang, J-W., Yang, M., Yagi, S., and Hoffman, R.M. Oral 5-FU is a more effective antimetastatic agent than UFT. *Anticancer Research* 24, 1353-1360, 2004.
 22. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer. *Cancer Res.* 64, 1828-1833, 2004.
 23. Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman RM, Browning JL.

AntiCancer Inc.

MetaMouse

- Targeting the lymphotoxin- β receptor with agonist antibodies as a potential cancer therapy. *Cancer Res.* 66, 9617-9624, 2006.
24. Ammons, W.S., Wang, J.W., Yang, Z., Tidmarsh, G.F., and Hoffman, R.M. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. *Neoplasia* 9, 625-633, 2007.
 25. Duan, J.X., Jiao, H., Kaizerman, J., Stanton, T., Evans, J.W., Lan, L., Lorente, G., Banica, M., Jung, D., Wang, J., Ma, H., Li, X., Yang, Z., Hoffman, R.M., Ammons, W.S., Hart, C.P., and Matteucci, M. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. *Journal of Medicinal Chemistry* 51, 2412-2420, 2008.
 26. Matsuo, Y., Raimondo, M., Woodward, T.A., Wallace, M.B., Gill, K.R., Tong, Z., Burdick, M.D., Yang, Z., Strieter, R.M., Hoffman, R.M., Guha, S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. *Int. J. Cancer* 125, 1027-1037, 2009.

Reviews

1. Hoffman, R.M. Orthotopic is orthodox: Why are orthotopic-transplant metastatic models different from all other models? *J. Cellular Biochem.* 56, 1-3, 1994.
2. Hoffman, R.M. Fertile seed and rich soil: Development of patient-like models of human cancer by surgical orthotopic implantation of intact tissue. *Update Series: Comprehensive Textbook of Oncology* 3, 1-10, Schimpff, S.C., et al, eds. Williams & Wilkins, Baltimore, 1996.
3. Hoffman, R.M. Fertile seed and rich soil: The development of clinically relevant models of human cancer by surgical orthotopic implantation of intact tissue. In: Teicher, B., ed. *Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval.* Totowa, NJ: Humana Press Inc., 127-144, 1997.
4. Hoffman, R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. *Investigational New Drugs* 17, 343-359, 1999.[PDF]
5. Hoffman, R.M. Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. *Cancer and Metastasis Reviews.* 17, 271-277, 1999.[PDF]
6. Hoffman, R.M. Clinically Accurate Orthotopic Mouse Models of Cancer. In: Brooks, S., and Schumacher, U., eds. *Metastasis Research Protocols. Vol. II. Analysis of Cell Behavior In Vitro and In Vivo.* Totowa, NJ: Humana Press Inc., 251-275, 2001.
7. Hoffman, R.M. Green Fluorescent Protein for Metastasis Research. In: Brooks, S., and Schumacher, U., eds. *Metastasis Research Protocols. Vol. II. Analysis of Cell Behavior In Vitro and In Vivo.* Totowa, NJ: Humana Press Inc., 285-298, 2001.
8. Hoffman, R.M. GFP-Expressing Metastatic-Cancer Mouse Models. In: Teicher, B., ed.

AntiCancer Inc.

MetaMouse

- Tumor Models in Cancer Research. Totowa, NJ: Humana Press Inc., 99-112, 2002.
9. Hoffman, R.M. Green fluorescent protein imaging of tumor cells in mice. *Lab Animal* 31, 34-41, 2002. metastatic
 10. Hoffman, R.M. Watching real-time metastasis in vivo. *Trends in Molecular Medicine*, 8(7), 354-355, 2002.
 11. Hoffman, R.M. Whole-body fluorescence imaging with Green Fluorescence Protein. In: Hicks, B.W., ed. *Methods in Molecular Biology*, Vol. 183: Green Fluorescent Protein: Applications and Protocols. Totowa, NJ: Humana Press, 135-148, 2002.
 12. Hoffman, R.M. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. *Lancet Oncology* 3, 546-556, 2002. [PDF]
 13. Hoffman, R.M. Orthotopic mouse models of Cancer. In: *Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval*, 2nd Ed., pp. 183-212. Teicher, B., Andrews, P.A., eds. Totowa, NJ: Humana Press, 2004.
 14. Glinsky, G.V., Glinskii, A.B., Stephenson A.J., Hoffman, R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. *J. Clin. Invest.* 113, 913-923, 2004 [PDF]
 15. Hoffman, R.M. Orthotopic metastatic (MetaMouse \Rightarrow) models for discovery and development of novel chemotherapy. In: *Methods in Molecular Medicine*, Vol. III: Chemosensitivity: Vol. II, pp. 297-322, *In Vivo Models, Imaging and Molecular Regulators*. Blumenthal, R., ed. ISBN #1-58829-586-9. Totowa, NJ: Humana Press, 2005. DOI #10.1226/1588295869.
 16. Hoffman, R.M. Advantages of multi-color fluorescent proteins for whole-body and in vivo cellular imaging. *Journal of Biomedical Optics* 10(4), 41202, AN #041202, 2005. [PDF]
 17. Hoffman, R.M. In vivo cell biology of cancer cells visualized with fluorescent proteins. In *in vivo cellular and molecular imaging* for Current Topics in Developmental Biology, Vol. 70, pp. 121-144. Ahrens, Eric T., ed. London: Elsevier Life Sciences, 2005. DOI: 10.1016/S0070-2153(05)70006-5. [PDF]
 18. Mack, G., Marshall, A. Lost in migration. *Nature Biotechnology* 28, 214-229, 2010 (See page 218, Box 3). Zhang, Q., Yang, M., Shen, J., Gerhold, L.M., Hoffman, R.M., Xing, H.R. The role of the intravascular microenvironment in spontaneous metastasis development. *International Journal of Cancer* 126, 2534-2541, 2010. [PDF]
 19. Hoffman, R. Orthotopic mouse models expressing fluorescent proteins for cancer drug discovery. *Expert Opin Drug Discov.* 5, 851-866, 2010.
 20. Hoffman, R.M. Imaging the steps of metastasis at the macro and cellular level with fluorescent proteins in real time (Chapter 6). In: *Tumor Models in Cancer Research*, vol. 2. Teicher, B.A., ed. Humana Press (c/o Springer Science+Business Media LLC), 125-166, 2011.
 21. Hoffman, R.M. Imageable clinically-relevant mouse models of cancer. In: *Methods in Molecular Biology: Metastasis Research Protocols*, 2nd ed., 1070, 141-170. Brooks, S.A., Dwek, M.,

AntiCancer Inc.

MetaMouse

- Schumacher, U., eds. Totowa, NJ: Humana Press Inc., 2014.
22. Hoffman, R.M. Imaging metastatic cell trafficking at the cellular level in vivo with fluorescent proteins. In: *Methods in Molecular Biology: Metastasis Research Protocols*, 2nd ed., 1070, 171-179. Brooks, S.A., Dwek, M., Schumacher, U., eds. Totowa, NJ: Humana Press Inc., 2014.
 23. Hoffman, R.M. The in vivo imaging revolution made by fluorescent proteins. In: *The Fluorescent Protein Revolution*, Day, R.N., Davidson, M.W., eds. Taylor and Francis Books, 2014, pp 309-324.
 24. Hoffman, R.M. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. *Nature Reviews Cancer* **15**, 451-452, 2015.
 25. Bouvet, M., Hoffman, R.M. Curative fluorescence guided surgery of gastrointestinal cancers developed in patient derived orthotopic xenograft mouse models. *J. Fluores Guided Surg.* **1**, 5-16, 2017.
 26. Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Murakami T, Unno M, Hoffman RM. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. *Cells.* 8(5). pii: E410. 2019.